Maize genes for controlling plant growth and organ size and their use in improving crop plants

ABSTRACT

The present invention provides polynucleotides and related polypeptides of the ZmARGOS gene family. The invention provides genomic sequence for the ZmARGOS genes. ZmARGOS is responsible for controlling plant growth, organ size and yield in crop plants.

CROSS REFERENCE

This application is a continuation of U.S. Ser. No. 14/028,695, filedSep. 17, 2013, which is a continuation of U.S. Ser. No. 12/846,017 filedJun. 29, 2010, now U.S. Pat. No. 8,575,422, issued Nov. 5, 2013, whichis a continuation of U.S. Ser. No. 12/464,144 filed May 12, 2009 nowU.S. Pat. No. 7,834,240, issued Nov. 16, 2010, which is a continuationof U.S. Ser. No. 11/692,977 filed Mar. 29, 2007 now U.S. Pat. No.7,550,575 issued Jun. 23, 2009, and also claims the benefit U.S.Provisional Application No. 60/788,123, filed Mar. 31, 2006, all ofwhich are incorporated herein by reference.

FIELD OF THE INVENTION

The invention relates generally to the field of molecular biology.

BACKGROUND OF THE INVENTION

The domestication of many plants has correlated with dramatic increasesin yield. Most phenotypic variation occurring in natural populations iscontinuous and is effected by multiple gene influences. Theidentification of specific genes responsible for the dramaticdifferences in yield, in domesticated plants, has become an importantfocus of agricultural research.

In Arabidopsis, one family of genes associated with plant changes thatrelate to improved yield in crops, the (ARGOS) Auxin-Regulated Geneinvolved in Organ Size gene is inducible by auxin. This gene isresponsible for the regulation of cell proliferation and organ growth.The Arabidopsis ARGOS is naturally expressed at a low level in variousyoung tissues including roots, inflorescence stems, flower, youngrosette leaves and silliques, but undetectable in mature leaves. Instudies by Hu, et al., (2003 Plant Cell 15:1951-61) and Hu, et al.,(2006 The Plant Journal 47(1):1-9), transgenic plants that ectopicallyover-express sense or antisense ARGOS cDNA display enlarged or reducedaerial organs, respectively. Alteration in organ size demonstrate inthese plants is associated with changes in cell number and not cellsize. The increased cell number is attributed to the duration of organgrowth in Arabidopsis.

The present invention includes the identification of the putative maizeARGOS genes, ZmARGOS 1-9 (SEQ ID NOS: 1, 3, 5, 40-45 and 71) that arerelated to the Arabidopsis ARGOS genes (SEQ ID NOS: 59, 60 and 61). Theortholog having the most similarity to Arabidopsis ARGOS (SEQ ID NO:59), is ZmARGOS 1 (SEQ ID NO: 1). ZmARGOS 1 and 2 (SEQ ID NOS: 1 and 3)expression in maize was primarily in the roots, early endosperm,immature ear and shoot and ear inflorescent meristems. The expression isassociated with actively growing tissues, and is found to a lesserdegree in the mature tissues. This finding is consistent with the notedpositive effect of the gene on regulating growth and cell proliferation.The ZmARGOS 3 gene (SEQ ID NO: 5) expressed in a wide spectrum oftissues and developmental stages.

Transgenic plants expressing ZmARGOS1 (SEQ ID NO: 1) show a positiveimpact on biomass accumulation and rate of maize plant growth, as wellas an increase in organ size. These maize genes will find utility forenhancing agronomic traits in maize (and other crops).

The present invention also includes the identification of ARGOS genes inother plant species. The rice gene family is represented by 8 familymembers. Nine members of the gene family were found in Sorghum bicolor.Five gene sequences were also found in Soybean (Glycine max). Threemembers of the ARGOS Arabidopsis gene family are disclosed herein.

BRIEF SUMMARY OF THE INVENTION

Compositions and methods for controlling plant growth and organ size forincreasing yield in a plant are provided. The compositions include ARGOSsequences from maize, soybean, arabidopsis, rice and sorghum.Compositions of the invention comprise amino acid sequences andnucleotide sequences selected from SEQ ID NOS: 1-37, 40-71 as well asvariants and fragments thereof.

Polynucleotides encoding the ARGOS sequences are provided in DNAconstructs for expression in a plant of interest. Expression cassettes,plants, plant cells, plant parts and seeds comprising the sequences ofthe invention are further provided. In specific embodiments, thepolynucleotide is operably linked to a constitutive promoter.

Methods for modulating the level of an ARGOS sequence in a plant orplant part is provided. The methods comprise introducing into a plant orplant part a heterologous polynucleotide comprising an ARGOS sequence ofthe invention. The level of ARGOS polypeptide can be increased ordecreased. Such method can be used to increase the yield in plants; inone embodiment, the method is used to increase grain yield in cereals.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: (as FIG. 1) Dendrogram illustrating the relationship between theARGOS polypeptides of this invention from various plant species: maize,rice, soybean, sorghum and arabidopsis.

FIG. 2: (as FIGS. 2A-2D) Alignment of the maize, rice, soybean, sorghumand arabidopsis polypeptide sequences with identification of conservedregions. The proteins have a well-conserved proline-rich region near theC-terminus. The N-termini are generally diverged. The proteins are quiteshort, ranging from 58 to 146, and averaging 110 amino acids.

FIG. 3: (as FIG. 3) Alignment of ZmARGOS 1, 2 and 3, with AtARGOS 1,highlighting their areas of consensus, and conservative substitutions.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Unless mentioned otherwise, thetechniques employed or contemplated herein are standard methodologieswell known to one of ordinary skill in the art. The materials, methodsand examples are illustrative only and not limiting. The following ispresented by way of illustration and is not intended to limit the scopeof the invention.

The present inventions now will be described more fully hereinafter withreference to the accompanying drawings, in which some, but not allembodiments of the invention are shown. Indeed, these inventions may beembodied in many different forms and should not be construed as limitedto the embodiments set forth herein; rather, these embodiments areprovided so that this disclosure will satisfy applicable legalrequirements. Like numbers refer to like elements throughout.

Many modifications and other embodiments of the inventions set forthherein will come to mind to one skilled in the art to which theseinventions pertain having the benefit of the teachings presented in theforegoing descriptions and the associated drawings. Therefore, it is tobe understood that the inventions are not to be limited to the specificembodiments disclosed and that modifications and other embodiments areintended to be included within the scope of the appended claims.Although specific terms are employed herein, they are used in a genericand descriptive sense only and not for purposes of limitation.

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of botany, microbiology, tissueculture, molecular biology, chemistry, biochemistry and recombinant DNAtechnology, which are within the skill of the art. Such techniques areexplained fully in the literature. See, e.g., Langenheim and Thimann,BOTANY: PLANT BIOLOGY AND ITS RELATION TO HUMAN AFFAIRS, John Wiley(1982); CELL CULTURE AND SOMATIC CELL GENETICS OF PLANTS, vol. 1, Vasil,ed. (1984); Stanier, et al., THE MICROBIAL WORLD, 5^(th) ed.,Prentice-Hall (1986); Dhringra and Sinclair, BASIC PLANT PATHOLOGYMETHODS, CRC Press (1985); Maniatis, et al., MOLECULAR CLONING: ALABORATORY MANUAL (1982); DNA CLONING, vols. I and II, Glover, ed.(1985); OLIGONUCLEOTIDE SYNTHESIS, Gait, ed. (1984); NUCLEIC ACIDHYBRIDIZATION, Hames and Higgins, eds. (1984); and the series METHODS INENZYMOLOGY, Colowick and Kaplan, eds, Academic Press, Inc., San Diego,Calif.

Units, prefixes and symbols may be denoted in their SI accepted form.Unless otherwise indicated, nucleic acids are written left to right in5′ to 3′ orientation; amino acid sequences are written left to right inamino to carboxy orientation, respectively. Numeric ranges are inclusiveof the numbers defining the range. Amino acids may be referred to hereinby either their commonly known three letter symbols or by the one-lettersymbols recommended by the IUPAC-IUB Biochemical NomenclatureCommission. Nucleotides, likewise, may be referred to by their commonlyaccepted single-letter codes. The terms defined below are more fullydefined by reference to the specification as a whole.

In describing the present invention, the following terms will beemployed, and are intended to be defined as indicated below.

By “microbe” is meant any microorganism (including both eukaryotic andprokaryotic microorganisms), such as fungi, yeast, bacteria,actinomycetes, algae and protozoa, as well as other unicellularstructures.

By “amplified” is meant the construction of multiple copies of a nucleicacid sequence or multiple copies complementary to the nucleic acidsequence using at least one of the nucleic acid sequences as a template.Amplification systems include the polymerase chain reaction (PCR)system, ligase chain reaction (LCR) system, nucleic acid sequence basedamplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicasesystems, transcription-based amplification system (TAS) and stranddisplacement amplification (SDA). See, e.g., DIAGNOSTIC MOLECULARMICROBIOLOGY: PRINCIPLES AND APPLICATIONS, Persing, et al., eds.,American Society for Microbiology, Washington, D.C. (1993). The productof amplification is termed an amplicon.

The term “conservatively modified variants” applies to both amino acidand nucleic acid sequences. With respect to particular nucleic acidsequences, conservatively modified variants refer to those nucleic acidsthat encode identical or conservatively modified variants of the aminoacid sequences. Because of the degeneracy of the genetic code, a largenumber of functionally identical nucleic acids encode any given protein.For instance, the codons GCA, GCC, GCG and GCU all encode the amino acidalanine. Thus, at every position where an alanine is specified by acodon, the codon can be altered to any of the corresponding codonsdescribed without altering the encoded polypeptide. Such nucleic acidvariations are “silent variations” and represent one species ofconservatively modified variation. Every nucleic acid sequence hereinthat encodes a polypeptide also describes every possible silentvariation of the nucleic acid. One of ordinary skill will recognize thateach codon in a nucleic acid (except AUG, which is ordinarily the onlycodon for methionine; one exception is Micrococcus rubens, for which GTGis the methionine codon (Ishizuka, et al., (1993) J. Gen. Microbiol.139:425-32) can be modified to yield a functionally identical molecule.Accordingly, each silent variation of a nucleic acid, which encodes apolypeptide of the present invention, is implicit in each describedpolypeptide sequence and incorporated herein by reference.

As to amino acid sequences, one of skill will recognize that individualsubstitutions, deletions or additions to a nucleic acid, peptide,polypeptide or protein sequence which alters, adds or deletes a singleamino acid or a small percentage of amino acids in the encoded sequenceis a “conservatively modified variant” when the alteration results inthe substitution of an amino acid with a chemically similar amino acid.Thus, any number of amino acid residues selected from the group ofintegers consisting of from 1 to 15 can be so altered. Thus, forexample, 1, 2, 3, 4, 5, 7 or 10 alterations can be made. Conservativelymodified variants typically provide similar biological activity as theunmodified polypeptide sequence from which they are derived. Forexample, substrate specificity, enzyme activity, or ligand/receptorbinding is generally at least 30%, 40%, 50%, 60%, 70%, 80% or 90%,preferably 60-90% of the native protein for it's native substrate.Conservative substitution tables providing functionally similar aminoacids are well known in the art.

The following six groups each contain amino acids that are conservativesubstitutions for one another:

1) Alanine (A), Serine (S), Threonine (T);

2) Aspartic acid (D), Glutamic acid (E);

3) Asparagine (N), Glutamine (Q);

4) Arginine (R), Lysine (K);

5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton, PROTEINS, W.H. Freeman and Co. (1984).

As used herein, “consisting essentially of” means the inclusion ofadditional sequences to an object polynucleotide where the additionalsequences do not selectively hybridize, under stringent hybridizationconditions, to the same cDNA as the polynucleotide and where thehybridization conditions include a wash step in 0.1×SSC and 0.1% sodiumdodecyl sulfate at 65° C.

By “encoding” or “encoded,” with respect to a specified nucleic acid, ismeant comprising the information for translation into the specifiedprotein. A nucleic acid encoding a protein may comprise non-translatedsequences (e.g., introns) within translated regions of the nucleic acid,or may lack such intervening non-translated sequences (e.g., as incDNA). The information by which a protein is encoded is specified by theuse of codons. Typically, the amino acid sequence is encoded by thenucleic acid using the “universal” genetic code. However, variants ofthe universal code, such as is present in some plant, animal and fungalmitochondria, the bacterium Mycoplasma capricolum (Yamao, et al., (1985)Proc. Natl. Acad. Sci. USA 82:2306-9) or the ciliate Macronucleus, maybe used when the nucleic acid is expressed using these organisms.

When the nucleic acid is prepared or altered synthetically, advantagecan be taken of known codon preferences of the intended host where thenucleic acid is to be expressed. For example, although nucleic acidsequences of the present invention may be expressed in bothmonocotyledonous and dicotyledonous plant species, sequences can bemodified to account for the specific codon preferences and GC contentpreferences of monocotyledonous plants or dicotyledonous plants as thesepreferences have been shown to differ (Murray, et al., (1989) NucleicAcids Res. 17:477-98 and herein incorporated by reference). Thus, themaize preferred codon for a particular amino acid might be derived fromknown gene sequences from maize. Maize codon usage for 28 genes frommaize plants is listed in Table 4 of Murray, et al., supra.

As used herein, “heterologous” in reference to a nucleic acid is anucleic acid that originates from a foreign species, or, if from thesame species, is substantially modified from its native form incomposition and/or genomic locus by deliberate human intervention. Forexample, a promoter operably linked to a heterologous structural gene isfrom a species different from that from which the structural gene wasderived or, if from the same species, one or both are substantiallymodified from their original form. A heterologous protein may originatefrom a foreign species or, if from the same species, is substantiallymodified from its original form by deliberate human intervention.

By “host cell” is meant a cell, which contains a vector and supports thereplication and/or expression of the expression vector. Host cells maybe prokaryotic cells such as E. coli, or eukaryotic cells such as yeast,insect, plant, amphibian or mammalian cells. Preferably, host cells aremonocotyledonous or dicotyledonous plant cells, including but notlimited to maize, sorghum, sunflower, soybean, wheat, alfalfa, rice,cotton, canola, barley, millet and tomato. A particularly preferredmonocotyledonous host cell is a maize host cell.

The term “hybridization complex” includes reference to a duplex nucleicacid structure formed by two single-stranded nucleic acid sequencesselectively hybridized with each other.

The term “introduced” in the context of inserting a nucleic acid into acell, means “transfection” or “transformation” or “transduction” andincludes reference to the incorporation of a nucleic acid into aeukaryotic or prokaryotic cell where the nucleic acid may beincorporated into the genome of the cell (e.g., chromosome, plasmid,plastid or mitochondrial DNA), converted into an autonomous replicon, ortransiently expressed (e.g., transfected mRNA).

The terms “isolated” refers to material, such as a nucleic acid or aprotein, which is substantially or essentially free from componentswhich normally accompany or interact with it as found in its naturallyoccurring environment. The isolated material optionally comprisesmaterial not found with the material in its natural environment. Nucleicacids, which are “isolated”, as defined herein, are also referred to as“heterologous” nucleic acids. Unless otherwise stated, the term “ARGOSnucleic acid” means a nucleic acid comprising a polynucleotide (“ARGOSpolynucleotide”) encoding a ARGOS polypeptide.

As used herein, “nucleic acid” includes reference to adeoxyribonucleotide or ribonucleotide polymer in either single- ordouble-stranded form, and unless otherwise limited, encompasses knownanalogues having the essential nature of natural nucleotides in thatthey hybridize to single-stranded nucleic acids in a manner similar tonaturally occurring nucleotides (e.g., peptide nucleic acids).

By “nucleic acid library” is meant a collection of isolated DNA or RNAmolecules, which comprise and substantially represent the entiretranscribed fraction of a genome of a specified organism. Constructionof exemplary nucleic acid libraries, such as genomic and cDNA libraries,is taught in standard molecular biology references such as Berger andKimmel, GUIDE TO MOLECULAR CLONING TECHNIQUES, from the series METHODSIN ENZYMOLOGY, vol. 152, Academic Press, Inc., San Diego, Calif. (1987);Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2^(nd) ed.,vols. 1-3 (1989); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel,et al., eds, Current Protocols, a joint venture between GreenePublishing Associates, Inc. and John Wiley & Sons, Inc. (1994Supplement).

As used herein “operably linked” includes reference to a functionallinkage between a first sequence, such as a promoter and a secondsequence, wherein the promoter sequence initiates and mediatestranscription of the DNA sequence corresponding to the second sequence.Generally, operably linked means that the nucleic acid sequences beinglinked are contiguous and, where necessary to join two protein codingregions, contiguous and in the same reading frame.

As used herein, the term “plant” includes reference to whole plants,plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cellsand progeny of same. Plant cell, as used herein includes, withoutlimitation, seeds suspension cultures, embryos, meristematic regions,callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollenand microspores. The class of plants, which can be used in the methodsof the invention, is generally as broad as the class of higher plantsamenable to transformation techniques, including both monocotyledonousand dicotyledonous plants including species from the genera: Cucurbita,Rosa, Vitis, Juglans, Fragaria, Lotus, Medicago, Onobrychis, Trifolium,Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus,Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura,Hyoscyamus, Lycopersicon, Nicotiana, Solanum, Petunia, Digitalis,Majorana, Ciahorium, Helianthus, Lactuca, Bromus, Asparagus,Antirrhinum, Heterocallis, Nemesis, Pelargonium, Panieum, Pennisetum,Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Pisum,Phaseolus, Lolium, Oryza, Avena, Hordeum, Secale, Allium and Triticum. Aparticularly preferred plant is Zea mays.

As used herein, “yield” includes reference to bushels per acre of agrain crop at harvest, as adjusted for grain moisture (15% typically).Grain moisture is measured in the grain at harvest. The adjusted testweight of grain is determined to be the weight in pounds per bushel,adjusted for grain moisture level at harvest.

As used herein, “polynucleotide” includes reference to adeoxyribopolynucleotide, ribopolynucleotide or analogs thereof that havethe essential nature of a natural ribonucleotide in that they hybridize,under stringent hybridization conditions, to substantially the samenucleotide sequence as naturally occurring nucleotides and/or allowtranslation into the same amino acid(s) as the naturally occurringnucleotide(s). A polynucleotide can be full-length or a subsequence of anative or heterologous structural or regulatory gene. Unless otherwiseindicated, the term includes reference to the specified sequence as wellas the complementary sequence thereof. Thus, DNAs or RNAs with backbonesmodified for stability or for other reasons are “polynucleotides” asthat term is intended herein. Moreover, DNAs or RNAs comprising unusualbases, such as inosine, or modified bases, such as tritylated bases, toname just two examples, are polynucleotides as the term is used herein.It will be appreciated that a great variety of modifications have beenmade to DNA and RNA that serve many useful purposes known to those ofskill in the art. The term polynucleotide as it is employed hereinembraces such chemically, enzymatically or metabolically modified formsof polynucleotides, as well as the chemical forms of DNA and RNAcharacteristic of viruses and cells, including inter alia, simple andcomplex cells.

The terms “polypeptide”, “peptide” and “protein” are usedinterchangeably herein to refer to a polymer of amino acid residues. Theterms apply to amino acid polymers in which one or more amino acidresidue is an artificial chemical analogue of a corresponding naturallyoccurring amino acid, as well as to naturally occurring amino acidpolymers.

As used herein “promoter” includes reference to a region of DNA upstreamfrom the start of transcription and involved in recognition and bindingof RNA polymerase and other proteins to initiate transcription. A “plantpromoter” is a promoter capable of initiating transcription in plantcells. Exemplary plant promoters include, but are not limited to, thosethat are obtained from plants, plant viruses and bacteria which comprisegenes expressed in plant cells such Agrobacterium or Rhizobium. Examplesare promoters that preferentially initiate transcription in certaintissues, such as leaves, roots, seeds, fibres, xylem vessels, tracheidsor sclerenchyma. Such promoters are referred to as “tissue preferred.” A“cell type” specific promoter primarily drives expression in certaincell types in one or more organs, for example, vascular cells in rootsor leaves. An “inducible” or “regulatable” promoter is a promoter, whichis under environmental control. Examples of environmental conditionsthat may effect transcription by inducible promoters include anaerobicconditions or the presence of light. Another type of promoter is adevelopmentally regulated promoter, for example, a promoter that drivesexpression during pollen development. Tissue preferred, cell typespecific, developmentally regulated and inducible promoters constitutethe class of “non-constitutive” promoters. A “constitutive” promoter isa promoter, which is active under most environmental conditions.

The term “ARGOS polypeptide” refers to one or more amino acid sequences.The term is also inclusive of fragments, variants, homologs, alleles orprecursors (e.g., preproproteins or proproteins) thereof. A “ARGOSprotein” comprises a ARGOS polypeptide. Unless otherwise stated, theterm “ARGOS nucleic acid” means a nucleic acid comprising apolynucleotide (“ARGOS polynucleotide”) encoding a ARGOS polypeptide.

As used herein “recombinant” includes reference to a cell or vector,that has been modified by the introduction of a heterologous nucleicacid or that the cell is derived from a cell so modified. Thus, forexample, recombinant cells express genes that are not found in identicalform within the native (non-recombinant) form of the cell or expressnative genes that are otherwise abnormally expressed, under expressed ornot expressed at all as a result of deliberate human intervention. Theterm “recombinant” as used herein does not encompass the alteration ofthe cell or vector by naturally occurring events (e.g., spontaneousmutation, natural transformation/transduction/transposition) such asthose occurring without deliberate human intervention.

As used herein, a “recombinant expression cassette” is a nucleic acidconstruct, generated recombinantly or synthetically, with a series ofspecified nucleic acid elements, which permit transcription of aparticular nucleic acid in a target cell. The recombinant expressioncassette can be incorporated into a plasmid, chromosome, mitochondrialDNA, plastid DNA, virus or nucleic acid fragment. Typically, therecombinant expression cassette portion of an expression vectorincludes, among other sequences, a nucleic acid to be transcribed and apromoter.

The term “residue” or “amino acid residue” or “amino acid” are usedinterchangeably herein to refer to an amino acid that is incorporatedinto a protein, polypeptide or peptide (collectively “protein”). Theamino acid may be a naturally occurring amino acid and, unless otherwiselimited, may encompass known analogs of natural amino acids that canfunction in a similar manner as naturally occurring amino acids.

The term “selectively hybridizes” includes reference to hybridization,under stringent hybridization conditions, of a nucleic acid sequence toa specified nucleic acid target sequence to a detectably greater degree(e.g., at least 2-fold over background) than its hybridization tonon-target nucleic acid sequences and to the substantial exclusion ofnon-target nucleic acids. Selectively hybridizing sequences typicallyhave about at least 40% sequence identity, preferably 60-90% sequenceidentity and most preferably 100% sequence identity (i.e.,complementary) with each other.

The terms “stringent conditions” or “stringent hybridization conditions”include reference to conditions under which a probe will hybridize toits target sequence, to a detectably greater degree than other sequences(e.g., at least 2-fold over background). Stringent conditions aresequence-dependent and will be different in different circumstances. Bycontrolling the stringency of the hybridization and/or washingconditions, target sequences can be identified which can be up to 100%complementary to the probe (homologous probing). Alternatively,stringency conditions can be adjusted to allow some mismatching insequences so that lower degrees of similarity are detected (heterologousprobing). Optimally, the probe is approximately 500 nucleotides inlength, but can vary greatly in length from less than 500 nucleotides toequal to the entire length of the target sequence.

Typically, stringent conditions will be those in which the saltconcentration is less than about 1.5 M Na ion, typically about 0.01 to1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and thetemperature is at least about 30° C. for short probes (e.g., 10 to 50nucleotides) and at least about 60° C. for long probes (e.g., greaterthan 50 nucleotides). Stringent conditions may also be achieved with theaddition of destabilizing agents such as formamide or Denhardt's.Exemplary low stringency conditions include hybridization with a buffersolution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecylsulphate) at 37° C. and a wash in 1× to 2×SSC (20×SSC=3.0 M NaCl/0.3 Mtrisodium citrate) at 50 to 55° C. Exemplary moderate stringencyconditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1%SDS at 37° C., and a wash in 0.5× to 1×SSC at 55 to 60° C. Exemplaryhigh stringency conditions include hybridization in 50% formamide, 1 MNaCl, 1% SDS at 37° C. and a wash in 0.1×SSC at 60 to 65° C. Specificityis typically the function of post-hybridization washes, the criticalfactors being the ionic strength and temperature of the final washsolution. For DNA-DNA hybrids, the T_(m), can be approximated from theequation of Meinkoth and Wahl, (1984) Anal. Biochem. 138:267-84:T_(m)=81.5° C.+16.6 (log M)+0.41 (% GC)−0.61 (% form)−500/L; where M isthe molarity of monovalent cations, % GC is the percentage of guanosineand cytosine nucleotides in the DNA, % form is the percentage offormamide in the hybridization solution, and L is the length of thehybrid in base pairs. The T_(m) is the temperature (under defined ionicstrength and pH) at which 50% of a complementary target sequencehybridizes to a perfectly matched probe. T_(m) is reduced by about 1° C.for each 1% of mismatching; thus, T_(m), hybridization and/or washconditions can be adjusted to hybridize to sequences of the desiredidentity. For example, if sequences with ≧90% identity are sought, theT_(m) can be decreased 10° C. Generally, stringent conditions areselected to be about 5° C. lower than the thermal melting point (T_(m))for the specific sequence and its complement at a defined ionic strengthand pH. However, severely stringent conditions can utilize ahybridization and/or wash at 1, 2, 3 or 4° C. lower than the thermalmelting point (T_(m)); moderately stringent conditions can utilize ahybridization and/or wash at 6, 7, 8, 9 or 10° C. lower than the thermalmelting point (T_(m)); low stringency conditions can utilize ahybridization and/or wash at 11, 12, 13, 14, 15 or 20° C. lower than thethermal melting point (T_(m)). Using the equation, hybridization andwash compositions, and desired T_(m), those of ordinary skill willunderstand that variations in the stringency of hybridization and/orwash solutions are inherently described. If the desired degree ofmismatching results in a T_(m) of less than 45° C. (aqueous solution) or32° C. (formamide solution) it is preferred to increase the SSCconcentration so that a higher temperature can be used. An extensiveguide to the hybridization of nucleic acids is found in Tijssen,LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULARBIOLOGY—HYBRIDIZATION WITH NUCLEIC ACID PROBES, part I, chapter 2,“Overview of principles of hybridization and the strategy of nucleicacid probe assays,” Elsevier, New York (1993); and CURRENT PROTOCOLS INMOLECULAR BIOLOGY, chapter 2, Ausubel, et al., eds, Greene Publishingand Wiley-Interscience, New York (1995). Unless otherwise stated, in thepresent application high stringency is defined as hybridization in4×SSC, 5×Denhardt's (5 g Ficoll, 5 g polyvinypyrrolidone, 5 g bovineserum albumin in 500 ml of water), 0.1 mg/ml boiled salmon sperm DNA and25 mM Na phosphate at 65° C., and a wash in 0.1×SSC, 0.1% SDS at 65° C.

As used herein, “transgenic plant” includes reference to a plant, whichcomprises within its genome a heterologous polynucleotide. Generally,the heterologous polynucleotide is stably integrated within the genomesuch that the polynucleotide is passed on to successive generations. Theheterologous polynucleotide may be integrated into the genome alone oras part of a recombinant expression cassette. “Transgenic” is usedherein to include any cell, cell line, callus, tissue, plant part orplant, the genotype of which has been altered by the presence ofheterologous nucleic acid including those transgenics initially soaltered as well as those created by sexual crosses or asexualpropagation from the initial transgenic. The term “transgenic” as usedherein does not encompass the alteration of the genome (chromosomal orextra-chromosomal) by conventional plant breeding methods or bynaturally occurring events such as random cross-fertilization,non-recombinant viral infection, non-recombinant bacterialtransformation, non-recombinant transposition or spontaneous mutation.

As used herein, “vector” includes reference to a nucleic acid used intransfection of a host cell and into which can be inserted apolynucleotide. Vectors are often replicons. Expression vectors permittranscription of a nucleic acid inserted therein.

The following terms are used to describe the sequence relationshipsbetween two or more nucleic acids or polynucleotides or polypeptides:(a) “reference sequence”, (b) “comparison window”, (c) “sequenceidentity”, (d) “percentage of sequence identity” and (e) “substantialidentity”.

As used herein, “reference sequence” is a defined sequence used as abasis for sequence comparison. A reference sequence may be a subset orthe entirety of a specified sequence; for example, as a segment of afull-length cDNA or gene sequence, or the complete cDNA or genesequence.

As used herein, “comparison window” means includes reference to acontiguous and specified segment of a polynucleotide sequence, whereinthe polynucleotide sequence may be compared to a reference sequence andwherein the portion of the polynucleotide sequence in the comparisonwindow may comprise additions or deletions (i.e., gaps) compared to thereference sequence (which does not comprise additions or deletions) foroptimal alignment of the two sequences. Generally, the comparison windowis at least 20 contiguous nucleotides in length, and optionally can be30, 40, 50, 100 or longer. Those of skill in the art understand that toavoid a high similarity to a reference sequence due to inclusion of gapsin the polynucleotide sequence a gap penalty is typically introduced andis subtracted from the number of matches.

Methods of alignment of nucleotide and amino acid sequences forcomparison are well known in the art. The local homology algorithm(BESTFIT) of Smith and Waterman, (1981) Adv. Appl. Math 2:482, mayconduct optimal alignment of sequences for comparison; by the homologyalignment algorithm (GAP) of Needleman and Wunsch, (1970) J. Mol. Biol.48:443-53; by the search for similarity method (Tfasta and Fasta) ofPearson and Lipman, (1988) Proc. Natl. Acad. Sci. USA 85:2444; bycomputerized implementations of these algorithms, including, but notlimited to: CLUSTAL in the PC/Gene program by Intelligenetics, MountainView, Calif., GAP, BESTFIT, BLAST, FASTA and TFASTA in the WisconsinGenetics Software Package®, Version 8 (available from Genetics ComputerGroup (GCG® programs (Accelrys, Inc., San Diego, Calif.)). The CLUSTALprogram is well described by Higgins and Sharp, (1988) Gene 73:237-44;Higgins and Sharp, (1989) CABIOS 5:151-3; Corpet, et al., (1988) NucleicAcids Res. 16:10881-90; Huang, et al., (1992) Computer Applications inthe Biosciences 8:155-65 and Pearson, et al., (1994) Meth. Mol. Biol.24:307-31. The preferred program to use for optimal global alignment ofmultiple sequences is PileUp (Feng and Doolittle, (1987) J. Mol. Evol.,25:351-60 which is similar to the method described by Higgins and Sharp,(1989) CABIOS 5:151-53 and hereby incorporated by reference). The BLASTfamily of programs which can be used for database similarity searchesincludes: BLASTN for nucleotide query sequences against nucleotidedatabase sequences; BLASTX for nucleotide query sequences againstprotein database sequences; BLASTP for protein query sequences againstprotein database sequences; TBLASTN for protein query sequences againstnucleotide database sequences and TBLASTX for nucleotide query sequencesagainst nucleotide database sequences. See, CURRENT PROTOCOLS INMOLECULAR BIOLOGY, Chapter 19, Ausubel, et al., eds., Greene Publishingand Wiley-Interscience, New York (1995).

GAP uses the algorithm of Needleman and Wunsch, supra, to find thealignment of two complete sequences that maximizes the number of matchesand minimizes the number of gaps. GAP considers all possible alignmentsand gap positions and creates the alignment with the largest number ofmatched bases and the fewest gaps. It allows for the provision of a gapcreation penalty and a gap extension penalty in units of matched bases.GAP must make a profit of gap creation penalty number of matches foreach gap it inserts. If a gap extension penalty greater than zero ischosen, GAP must, in addition, make a profit for each gap inserted ofthe length of the gap times the gap extension penalty. Default gapcreation penalty values and gap extension penalty values in Version 10of the Wisconsin Genetics Software Package® are 8 and 2, respectively.The gap creation and gap extension penalties can be expressed as aninteger selected from the group of integers consisting of from 0 to 100.Thus, for example, the gap creation and gap extension penalties can be0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or greater.

GAP presents one member of the family of best alignments. There may bemany members of this family, but no other member has a better quality.GAP displays four figures of merit for alignments: Quality, Ratio,Identity and Similarity. The Quality is the metric maximized in order toalign the sequences. Ratio is the quality divided by the number of basesin the shorter segment. Percent Identity is the percent of the symbolsthat actually match. Percent Similarity is the percent of the symbolsthat are similar. Symbols that are across from gaps are ignored. Asimilarity is scored when the scoring matrix value for a pair of symbolsis greater than or equal to 0.50, the similarity threshold. The scoringmatrix used in Version 10 of the Wisconsin Genetics Software Package® isBLOSUM62 (see, Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA89:10915).

Unless otherwise stated, sequence identity/similarity values providedherein refer to the value obtained using the BLAST 2.0 suite of programsusing default parameters (Altschul, et al., (1997) Nucleic Acids Res.25:3389-402).

As those of ordinary skill in the art will understand, BLAST searchesassume that proteins can be modeled as random sequences. However, manyreal proteins comprise regions of nonrandom sequences, which may behomopolymeric tracts, short-period repeats, or regions enriched in oneor more amino acids. Such low-complexity regions may be aligned betweenunrelated proteins even though other regions of the protein are entirelydissimilar. A number of low-complexity filter programs can be employedto reduce such low-complexity alignments. For example, the SEG (Wootenand Federhen, (1993) Comput. Chem. 17:149-63) and XNU (Claverie andStates, (1993) Comput. Chem. 17:191-201) low-complexity filters can beemployed alone or in combination.

As used herein, “sequence identity” or “identity” in the context of twonucleic acid or polypeptide sequences includes reference to the residuesin the two sequences, which are the same when aligned for maximumcorrespondence over a specified comparison window. When percentage ofsequence identity is used in reference to proteins it is recognized thatresidue positions which are not identical often differ by conservativeamino acid substitutions, where amino acid residues are substituted forother amino acid residues with similar chemical properties (e.g., chargeor hydrophobicity) and therefore do not change the functional propertiesof the molecule. Where sequences differ in conservative substitutions,the percent sequence identity may be adjusted upwards to correct for theconservative nature of the substitution. Sequences, which differ by suchconservative substitutions, are said to have “sequence similarity” or“similarity.” Means for making this adjustment are well known to thoseof skill in the art. Typically this involves scoring a conservativesubstitution as a partial rather than a full mismatch, therebyincreasing the percentage sequence identity. Thus, for example, where anidentical amino acid is given a score of 1 and a non-conservativesubstitution is given a score of zero, a conservative substitution isgiven a score between zero and 1. The scoring of conservativesubstitutions is calculated, e.g., according to the algorithm of Meyersand Miller, (1988) Computer Applic. Biol. Sci. 4:11-17, e.g., asimplemented in the program PC/GENE (Intelligenetics, Mountain View,Calif., USA).

As used herein, “percentage of sequence identity” means the valuedetermined by comparing two optimally aligned sequences over acomparison window, wherein the portion of the polynucleotide sequence inthe comparison window may comprise additions or deletions (i.e., gaps)as compared to the reference sequence (which does not comprise additionsor deletions) for optimal alignment of the two sequences. The percentageis calculated by determining the number of positions at which theidentical nucleic acid base or amino acid residue occurs in bothsequences to yield the number of matched positions, dividing the numberof matched positions by the total number of positions in the window ofcomparison and multiplying the result by 100 to yield the percentage ofsequence identity.

The term “substantial identity” of polynucleotide sequences means that apolynucleotide comprises a sequence that has between 50-100% sequenceidentity, preferably at least 50% sequence identity, preferably at least60% sequence identity, preferably at least 70%, more preferably at least80%, more preferably at least 90% and most preferably at least 95%,compared to a reference sequence using one of the alignment programsdescribed using standard parameters. One of skill will recognize thatthese values can be appropriately adjusted to determine correspondingidentity of proteins encoded by two nucleotide sequences by taking intoaccount codon degeneracy, amino acid similarity, reading framepositioning and the like. Substantial identity of amino acid sequencesfor these purposes normally means sequence identity of between 55-100%,preferably at least 55%, preferably at least 60%, more preferably atleast 70%, 80%, 90% and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identicalis if two molecules hybridize to each other under stringent conditions.The degeneracy of the genetic code allows for many amino acidssubstitutions that lead to variety in the nucleotide sequence that codefor the same amino acid, hence it is possible that the DNA sequencecould code for the same polypeptide but not hybridize to each otherunder stringent conditions. This may occur, e.g., when a copy of anucleic acid is created using the maximum codon degeneracy permitted bythe genetic code. One indication that two nucleic acid sequences aresubstantially identical is that the polypeptide, which the first nucleicacid encodes, is immunologically cross reactive with the polypeptideencoded by the second nucleic acid.

The terms “substantial identity” in the context of a peptide indicatesthat a peptide comprises a sequence with between 55-100% sequenceidentity to a reference sequence preferably at least 55% sequenceidentity, preferably 60%, preferably 70%, more preferably 80%, mostpreferably at least 90% or 95% sequence identity to the referencesequence over a specified comparison window. Preferably, optimalalignment is conducted using the homology alignment algorithm ofNeedleman and Wunsch, supra. An indication that two peptide sequencesare substantially identical is that one peptide is immunologicallyreactive with antibodies raised against the second peptide. Thus, apeptide is substantially identical to a second peptide, for example,where the two peptides differ only by a conservative substitution. Inaddition, a peptide can be substantially identical to a second peptidewhen they differ by a non-conservative change if the epitope that theantibody recognizes is substantially identical. Peptides, which are“substantially similar” share sequences as, noted above except thatresidue positions, which are not identical, may differ by conservativeamino acid changes.

The invention discloses ARGOS polynucleotides and polypeptides. Thenovel nucleotides and proteins of the invention have an expressionpattern which indicates that they regulate cell number and thus play animportant role in plant development. The polynucleotides are expressedin various plant tissues. The polynucleotides and polypeptides thusprovide an opportunity to manipulate plant development to alter seed andvegetative tissue development, timing or composition. This may be usedto create a sterile plant, a seedless plant or a plant with alteredendosperm composition.

Nucleic Acids

The present invention provides, inter alia, isolated nucleic acids ofRNA, DNA and analogs and/or chimeras thereof, comprising a ARGOSpolynucleotide.

The present invention also includes polynucleotides optimized forexpression in different organisms. For example, for expression of thepolynucleotide in a maize plant, the sequence can be altered to accountfor specific codon preferences and to alter GC content as according toMurray, et al., supra. Maize codon usage for 28 genes from maize plantsis listed in Table 4 of Murray, et al., supra.

The ARGOS nucleic acids of the present invention comprise isolated ARGOSpolynucleotides which are inclusive of:

-   -   (a) a polynucleotide encoding a ARGOS polypeptide and        conservatively modified and polymorphic variants thereof;    -   (b) a polynucleotide having at least 70% sequence identity with        polynucleotides of (a) or (b);    -   (c) complementary sequences of polynucleotides of (a) or (b).        The following table, Table 1, lists the specific identities of        the polynucleotides and polypeptides and disclosed herein.

TABLE 1 Polynucleotide/ Gene name Plant species Polypeptide SEQ ID NO:ZmARGOS1 Zea mays Polynucleotide SEQ ID NO: 1 Polypeptide SEQ ID NO: 2Genomic SEQ ID NO: 71 sequence ZmARGOS2 Zea mays Polynucleotide SEQ IDNO: 3 Polypeptide SEQ ID NO: 4 ZmARGOS3 Zea mays Polynucleotide SEQ IDNO: 5 Polypeptide SEQ ID NO: 6 ZmARGOS4 Zea mays Polynucleotide SEQ IDNO: 7 Polypeptide SEQ ID NO: 40 ZmARGOS5 Zea mays Polynucleotide SEQ IDNO: 8 Polypeptide SEQ ID NO: 41 ZmARGOS6 Zea mays Polynucleotide SEQ IDNO: 9 Polypeptide SEQ ID NO: 42 ZmARGOS7 Zea mays Polynucleotide SEQ IDNO: 10 Polypeptide SEQ ID NO: 43 ZmARGOS8 Zea mays Polynucleotide SEQ IDNO: 11 Polypeptide SEQ ID NO: 44 ZmARGOS9 Zea mays Polynucleotide SEQ IDNO: 12 Polypeptide SEQ ID NO: 45 OsARGOS1 Oryza sativa PolynucleotideSEQ ID NO: 13 Polypeptide SEQ ID NO: 46 OsARGOS2 Oryza sativaPolynucleotide SEQ ID NO: 14 Polypeptide SEQ ID NO: 47 OsARGOS3 Oryzasativa Polynucleotide SEQ ID NO: 15 Polypeptide SEQ ID NO: 48 OsARGOS4Oryza sativa Polynucleotide SEQ ID NO: 16 Polypeptide SEQ ID NO: 49OsARGOS5 Oryza sativa Polynucleotide SEQ ID NO: 17 Polypeptide SEQ IDNO: 50 OsARGOS6 Oryza sativa Polynucleotide SEQ ID NO: 18 PolypeptideSEQ ID NO: 51 OsARGOS7 Oryza sativa Polynucleotide SEQ ID NO: 19Polypeptide SEQ ID NO: 52 OsARGOS8 Oryza sativa Polynucleotide SEQ IDNO: 20 Polypeptide SEQ ID NO: 53 GmARGOS1 Glycine max Polynucleotide SEQID NO: 21 Polypeptide SEQ ID NO: 54 GmARGOS2 Glycine max PolynucleotideSEQ ID NO: 22 Polypeptide SEQ ID NO: 55 GmARGOS3 Glycine maxPolynucleotide SEQ ID NO: 23 Polypeptide SEQ ID NO: 56 GmARGOS4 Glycinemax Polynucleotide SEQ ID NO: 24 Polypeptide SEQ ID NO: 57 GmARGOS5Glycine max Polynucleotide SEQ ID NO: 25 Polypeptide SEQ ID NO: 58SbARGOS1 Sorghum bicolor Polynucleotide SEQ ID NO: 29 Polypeptide SEQ IDNO: 62 SbARGOS2 Sorghum bicolor Polynucleotide SEQ ID NO: 30 PolypeptideSEQ ID NO: 63 SbARGOS3 Sorghum bicolor Polynucleotide SEQ ID NO: 31Polypeptide SEQ ID NO: 64 SbARGOS4 Sorghum bicolor Polynucleotide SEQ IDNO: 32 Polypeptide SEQ ID NO: 65 SbARGOS5 Sorghum bicolor PolynucleotideSEQ ID NO: 33 Polypeptide SEQ ID NO: 66 SbARGOS6 Sorghum bicolorPolynucleotide SEQ ID NO: 34 Polypeptide SEQ ID NO: 67 SbARGOS7 Sorghumbicolor Polynucleotide SEQ ID NO: 35 Polypeptide SEQ ID NO: 68 SbARGOS8Sorghum bicolor Polynucleotide SEQ ID NO: 36 Polypeptide SEQ ID NO: 69SbARGOS9 Sorghum bicolor Polynucleotide SEQ ID NO: 37 Polypeptide SEQ IDNO: 70 AtARGOS1 Arabidopsis thaliana Polynucleotide SEQ ID NO: 26Polypeptide SEQ ID NO: 59 AtARGOS2 Arabidopsis thaliana PolynucleotideSEQ ID NO: 27 Polypeptide SEQ ID NO: 60 AtARGOS3 Arabidopsis thalianaPolynucleotide SEQ ID NO: 28 Polypeptide SEQ ID NO: 61

Construction of Nucleic Acids

The isolated nucleic acids of the present invention can be made using(a) standard recombinant methods, (b) synthetic techniques orcombinations thereof. In some embodiments, the polynucleotides of thepresent invention will be cloned, amplified or otherwise constructedfrom a fungus or bacteria.

The nucleic acids may conveniently comprise sequences in addition to apolynucleotide of the present invention. For example, a multi-cloningsite comprising one or more endonuclease restriction sites may beinserted into the nucleic acid to aid in isolation of thepolynucleotide. Also, translatable sequences may be inserted to aid inthe isolation of the translated polynucleotide of the present invention.For example, a hexa-histidine marker sequence provides a convenientmeans to purify the proteins of the present invention. The nucleic acidof the present invention—excluding the polynucleotide sequence—isoptionally a vector, adapter or linker for cloning and/or expression ofa polynucleotide of the present invention. Additional sequences may beadded to such cloning and/or expression sequences to optimize theirfunction in cloning and/or expression, to aid in isolation of thepolynucleotide or to improve the introduction of the polynucleotide intoa cell. Typically, the length of a nucleic acid of the present inventionless the length of its polynucleotide of the present invention is lessthan 20 kilobase pairs, often less than 15 kb and frequently less than10 kb. Use of cloning vectors, expression vectors, adapters and linkersis well known in the art. Exemplary nucleic acids include such vectorsas: M13, lambda ZAP Express, lambda ZAP II, lambda gt10, lambda gt11,pBK-CMV, pBK-RSV, pBluescript II, lambda DASH II, lambda EMBL 3, lambdaEMBL 4, pWE15, SuperCos 1, SurfZap, Uni-ZAP, pBC, pBS+/−, pSG5, pBK,pCR-Script, pET, pSPUTK, p3′SS, pGEM, pSK+/−, pGEX, pSPORTI and II,pOPRSVI CAT, pOPI3 CAT, pXT1, pSG5, pPbac, pMbac, pMC1neo, pOG44, pOG45,pFRTβGAL, pNEOβGAL, pRS403, pRS404, pRS405, pRS406, pRS413, pRS414,pRS415, pRS416, lambda MOSSIox and lambda MOSElox. Optional vectors forthe present invention, include but are not limited to, lambda ZAP II andpGEX. For a description of various nucleic acids see, e.g., StratageneCloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, Calif.) and,Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, Ill.).

Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be preparedby direct chemical synthesis by methods such as the phosphotriestermethod of Narang, et al., (1979) Meth. Enzymol. 68:90-9; thephosphodiester method of Brown, et al., (1979) Meth. Enzymol. 68:109-51;the diethylphosphoramidite method of Beaucage, et al., (1981) Tetra.Letts. 22(20):1859-62; the solid phase phosphoramidite triester methoddescribed by Beaucage, et al., supra, e.g., using an automatedsynthesizer, e.g., as described in Needham-VanDevanter, et al., (1984)Nucleic Acids Res. 12:6159-68 and the solid support method of U.S. Pat.No. 4,458,066. Chemical synthesis generally produces a single strandedoligonucleotide. This may be converted into double stranded DNA byhybridization with a complementary sequence or by polymerization with aDNA polymerase using the single strand as a template. One of skill willrecognize that while chemical synthesis of DNA is limited to sequencesof about 100 bases, longer sequences may be obtained by the ligation ofshorter sequences.

UTRs and Codon Preference

In general, translational efficiency has been found to be regulated byspecific sequence elements in the 5′ non-coding or untranslated region(5′ UTR) of the RNA. Positive sequence motifs include translationalinitiation consensus sequences (Kozak, (1987) Nucleic Acids Res.15:8125) and the 5<G> 7 methyl GpppG RNA cap structure (Drummond, etal., (1985) Nucleic Acids Res. 13:7375). Negative elements includestable intramolecular 5′ UTR stem-loop structures (Muesing, et al.,(1987) Cell 48:691) and AUG sequences or short open reading framespreceded by an appropriate AUG in the 5′ UTR (Kozak, supra, Rao, et al.,(1988) Mol. and Cell. Biol. 8:284). Accordingly, the present inventionprovides 5′ and/or 3′ UTR regions for modulation of translation ofheterologous coding sequences.

Further, the polypeptide-encoding segments of the polynucleotides of thepresent invention can be modified to alter codon usage. Altered codonusage can be employed to alter translational efficiency and/or tooptimize the coding sequence for expression in a desired host or tooptimize the codon usage in a heterologous sequence for expression inmaize. Codon usage in the coding regions of the polynucleotides of thepresent invention can be analyzed statistically using commerciallyavailable software packages such as “Codon Preference” available fromthe University of Wisconsin Genetics Computer Group. See, Devereaux, etal., (1984) Nucleic Acids Res. 12:387-395; or MacVector 4.1 (EastmanKodak Co., New Haven, Conn.). Thus, the present invention provides acodon usage frequency characteristic of the coding region of at leastone of the polynucleotides of the present invention. The number ofpolynucleotides (3 nucleotides per amino acid) that can be used todetermine a codon usage frequency can be any integer from 3 to thenumber of polynucleotides of the present invention as provided herein.Optionally, the polynucleotides will be full-length sequences. Anexemplary number of sequences for statistical analysis can be at least1, 5, 10, 20, 50 or 100.

Sequence Shuffling

The present invention provides methods for sequence shuffling usingpolynucleotides of the present invention, and compositions resultingtherefrom. Sequence shuffling is described in PCT Publication Number1996/19256. See also, Zhang, et al., (1997) Proc. Natl. Acad. Sci. USA94:4504-9 and Zhao, et al., (1998) Nature Biotech 16:258-61. Generally,sequence shuffling provides a means for generating libraries ofpolynucleotides having a desired characteristic, which can be selectedor screened for. Libraries of recombinant polynucleotides are generatedfrom a population of related sequence polynucleotides, which comprisesequence regions, which have substantial sequence identity and can behomologously recombined in vitro or in vivo. The population ofsequence-recombined polynucleotides comprises a subpopulation ofpolynucleotides which possess desired or advantageous characteristicsand which can be selected by a suitable selection or screening method.The characteristics can be any property or attribute capable of beingselected for or detected in a screening system, and may includeproperties of: an encoded protein, a transcriptional element, a sequencecontrolling transcription, RNA processing, RNA stability, chromatinconformation, translation or other expression property of a gene ortransgene, a replicative element, a protein-binding element or the like,such as any feature which confers a selectable or detectable property.In some embodiments, the selected characteristic will be an alteredK_(m) and/or K_(cat) over the wild-type protein as provided herein. Inother embodiments, a protein or polynucleotide generated from sequenceshuffling will have a ligand binding affinity greater than thenon-shuffled wild-type polynucleotide. In yet other embodiments, aprotein or polynucleotide generated from sequence shuffling will have analtered pH optimum as compared to the non-shuffled wild-typepolynucleotide. The increase in such properties can be at least 110%,120%, 130%, 140% or greater than 150% of the wild-type value.

Recombinant Expression Cassettes

The present invention further provides recombinant expression cassettescomprising a nucleic acid of the present invention. A nucleic acidsequence coding for the desired polynucleotide of the present invention,for example a cDNA or a genomic sequence encoding a polypeptide longenough to code for an active protein of the present invention, can beused to construct a recombinant expression cassette which can beintroduced into the desired host cell. A recombinant expression cassettewill typically comprise a polynucleotide of the present inventionoperably linked to transcriptional initiation regulatory sequences whichwill direct the transcription of the polynucleotide in the intended hostcell, such as tissues of a transformed plant.

For example, plant expression vectors may include (1) a cloned plantgene under the transcriptional control of 5′ and 3′ regulatory sequencesand (2) a dominant selectable marker. Such plant expression vectors mayalso contain, if desired, a promoter regulatory region (e.g., oneconferring inducible or constitutive, environmentally- ordevelopmentally-regulated, or cell- or tissue-specific/selectiveexpression), a transcription initiation start site, a ribosome bindingsite, an RNA processing signal, a transcription termination site and/ora polyadenylation signal.

A plant promoter fragment can be employed which will direct expressionof a polynucleotide of the present invention in all tissues of aregenerated plant. Such promoters are referred to herein as“constitutive” promoters and are active under most environmentalconditions and states of development or cell differentiation. Examplesof constitutive promoters include the 1′- or 2′-promoter derived fromT-DNA of Agrobacterium tumefaciens, the Smas promoter, the cinnamylalcohol dehydrogenase promoter (U.S. Pat. No. 5,683,439), the Nospromoter, the rubisco promoter, the GRP1-8 promoter, the 35S promoterfrom cauliflower mosaic virus (CaMV), as described in Odell, et al.,(1985) Nature 313:810-2; rice actin (McElroy, et al., (1990) Plant Cell163-171); ubiquitin (Christensen, et al., (1992) Plant Mol. Biol.12:619-632 and Christensen, et al., (1992) Plant Mol. Biol. 18:675-89);pEMU (Last, et al., (1991) Theor. Appl. Genet. 81:581-8); MAS (Velten,et al., (1984) EMBO J. 3:2723-30) and maize H3 histone (Lepetit, et al.,(1992) Mol. Gen. Genet. 231:276-85 and Atanassvoa, et al., (1992) PlantJournal 2(3):291-300); ALS promoter, as described in PCT ApplicationNumber WO 1996/30530; GOS2 (U.S. Pat. No. 6,504,083) and othertranscription initiation regions from various plant genes known to thoseof skill. For the present invention ubiquitin is the preferred promoterfor expression in monocot plants.

Alternatively, the plant promoter can direct expression of apolynucleotide of the present invention in a specific tissue or may beotherwise under more precise environmental or developmental control.Such promoters are referred to here as “inducible” promoters (Rab17,RAD29). Environmental conditions that may effect transcription byinducible promoters include pathogen attack, anaerobic conditions, orthe presence of light. Examples of inducible promoters are the Adh1promoter, which is inducible by hypoxia or cold stress, the Hsp70promoter, which is inducible by heat stress, and the PPDK promoter,which is inducible by light.

Examples of promoters under developmental control include promoters thatinitiate transcription only, or preferentially, in certain tissues, suchas leaves, roots, fruit, seeds or flowers. The operation of a promotermay also vary depending on its location in the genome. Thus, aninducible promoter may become fully or partially constitutive in certainlocations.

If polypeptide expression is desired, it is generally desirable toinclude a polyadenylation region at the 3′-end of a polynucleotidecoding region. The polyadenylation region can be derived from a varietyof plant genes, or from T-DNA. The 3′ end sequence to be added can bederived from, for example, the nopaline synthase or octopine synthasegenes or alternatively from another plant gene or less preferably fromany other eukaryotic gene. Examples of such regulatory elements include,but are not limited to, 3′ termination and/or polyadenylation regionssuch as those of the Agrobacterium tumefaciens nopaline synthase (nos)gene (Bevan, et al., (1983) Nucleic Acids Res. 12:369-85); the potatoproteinase inhibitor II (PINII) gene (Keil, et al., (1986) Nucleic AcidsRes. 14:5641-50 and An, et al., (1989) Plant Cell 1:115-22) and the CaMV19S gene (Mogen, et al., (1990) Plant Cell 2:1261-72).

An intron sequence can be added to the 5′ untranslated region or thecoding sequence of the partial coding sequence to increase the amount ofthe mature message that accumulates in the cytosol. Inclusion of aspliceable intron in the transcription unit in both plant and animalexpression constructs has been shown to increase gene expression at boththe mRNA and protein levels up to 1000-fold (Buchman and Berg, (1988)Mol. Cell Biol. 8:4395-4405; Callis, et al., (1987) Genes Dev.1:1183-200). Such intron enhancement of gene expression is typicallygreatest when placed near the 5′ end of the transcription unit. Use ofmaize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are knownin the art. See generally, THE MAIZE HANDBOOK, Chapter 116, Freeling andWalbot, eds., Springer, New York (1994).

Plant signal sequences, including, but not limited to, signal-peptideencoding DNA/RNA sequences which target proteins to the extracellularmatrix of the plant cell (Dratewka-Kos, et al., (1989) J. Biol. Chem.264:4896-900), such as the Nicotiana plumbaginifolia extension gene(DeLoose, et al., (1991) Gene 99:95-100); signal peptides which targetproteins to the vacuole, such as the sweet potato sporamin gene(Matsuka, et al., (1991) Proc. Natl. Acad. Sci. USA 88:834) and thebarley lectin gene (Wilkins, et al., (1990) Plant Cell, 2:301-13);signal peptides which cause proteins to be secreted, such as that ofPRIb (Lind, et al., (1992) Plant Mol. Biol. 18:47-53) or the barleyalpha amylase (BAA) (Rahmatullah, et al., (1989) Plant Mol. Biol. 12:119and hereby incorporated by reference) or signal peptides which targetproteins to the plastids such as that of rapeseed enoyl-Acp reductase(Verwaert, et al., (1994) Plant Mol. Biol. 26:189-202) are useful in theinvention. The barley alpha amylase signal sequence fused to the ARGOSpolynucleotide is the preferred construct for expression in maize forthe present invention.

The vector comprising the sequences from a polynucleotide of the presentinvention will typically comprise a marker gene, which confers aselectable phenotype on plant cells. Usually, the selectable marker genewill encode antibiotic resistance, with suitable genes including genescoding for resistance to the antibiotic spectinomycin (e.g., the aadagene), the streptomycin phosphotransferase (SPT) gene coding forstreptomycin resistance, the neomycin phosphotransferase (NPTII) geneencoding kanamycin or geneticin resistance, the hygromycinphosphotransferase (HPT) gene coding for hygromycin resistance, genescoding for resistance to herbicides which act to inhibit the action ofacetolactate synthase (ALS), in particular the sulfonylurea-typeherbicides (e.g., the acetolactate synthase (ALS) gene containingmutations leading to such resistance in particular the S4 and/or Hramutations), genes coding for resistance to herbicides which act toinhibit action of glutamine synthase, such as phosphinothricin or basta(e.g., the bar gene) or other such genes known in the art. The bar geneencodes resistance to the herbicide basta and the ALS gene encodesresistance to the herbicide chlorsulfuron.

Typical vectors useful for expression of genes in higher plants are wellknown in the art and include vectors derived from the tumor-inducing(Ti) plasmid of Agrobacterium tumefaciens described by Rogers, et al.,(1987) Meth. Enzymol. 153:253-77. These vectors are plant integratingvectors in that on transformation, the vectors integrate a portion ofvector DNA into the genome of the host plant. Exemplary A. tumefaciensvectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl, et al.,(1987) Gene 61:1-11 and Berger, et al., (1989) Proc. Natl. Acad. Sci.USA, 86:8402-6. Another useful vector herein is plasmid pB1101.2 that isavailable from CLONTECH Laboratories, Inc. (Palo Alto, Calif.).

Expression of Proteins in Host Cells

Using the nucleic acids of the present invention, one may express aprotein of the present invention in a recombinantly engineered cell suchas bacteria, yeast, insect, mammalian or preferably plant cells. Thecells produce the protein in a non-natural condition (e.g., in quantity,composition, location and/or time), because they have been geneticallyaltered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in thenumerous expression systems available for expression of a nucleic acidencoding a protein of the present invention. No attempt to describe indetail the various methods known for the expression of proteins inprokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding aprotein of the present invention will typically be achieved by operablylinking, for example, the DNA or cDNA to a promoter (which is eitherconstitutive or inducible), followed by incorporation into an expressionvector. The vectors can be suitable for replication and integration ineither prokaryotes or eukaryotes. Typical expression vectors containtranscription and translation terminators, initiation sequences, andpromoters useful for regulation of the expression of the DNA encoding aprotein of the present invention. To obtain high level expression of acloned gene, it is desirable to construct expression vectors whichcontain, at the minimum, a strong promoter, such as ubiquitin, to directtranscription, a ribosome binding site for translational initiation anda transcription/translation terminator. Constitutive promoters areclassified as providing for a range of constitutive expression. Thus,some are weak constitutive promoters, and others are strong constitutivepromoters. Generally, by “weak promoter” is intended a promoter thatdrives expression of a coding sequence at a low level. By “low level” isintended at levels of about 1/10,000 transcripts to about 1/100,000transcripts to about 1/500,000 transcripts. Conversely, a “strongpromoter” drives expression of a coding sequence at a “high level” orabout 1/10 transcripts to about 1/100 transcripts to about 1/1,000transcripts.

One of skill would recognize that modifications could be made to aprotein of the present invention without diminishing its biologicalactivity. Some modifications may be made to facilitate the cloning,expression or incorporation of the targeting molecule into a fusionprotein. Such modifications are well known to those of skill in the artand include, for example, a methionine added at the amino terminus toprovide an initiation site or additional amino acids (e.g., poly His)placed on either terminus to create conveniently located restrictionsites or termination codons or purification sequences.

Expression in Prokaryotes

Prokaryotic cells may be used as hosts for expression. Prokaryotes mostfrequently are represented by various strains of E. coli; however, othermicrobial strains may also be used. Commonly used prokaryotic controlsequences which are defined herein to include promoters fortranscription initiation, optionally with an operator, along withribosome binding site sequences, include such commonly used promoters asthe beta lactamase (penicillinase) and lactose (lac) promoter systems(Chang, et al., (1977) Nature 198:1056), the tryptophan (trp) promotersystem (Goeddel, et al., (1980) Nucleic Acids Res. 8:4057) and thelambda derived P L promoter and N-gene ribosome binding site (Shimatake,et al., (1981) Nature 292:128). The inclusion of selection markers inDNA vectors transfected in E. coli is also useful. Examples of suchmarkers include genes specifying resistance to ampicillin, tetracyclineor chloramphenicol.

The vector is selected to allow introduction of the gene of interestinto the appropriate host cell. Bacterial vectors are typically ofplasmid or phage origin. Appropriate bacterial cells are infected withphage vector particles or transfected with naked phage vector DNA. If aplasmid vector is used, the bacterial cells are transfected with theplasmid vector DNA. Expression systems for expressing a protein of thepresent invention are available using Bacillus sp. and Salmonella(Palva, et al., (1983) Gene 22:229-35; Mosbach, et al., (1983) Nature302:543-5). The pGEX-4T-1 plasmid vector from Pharmacia is the preferredE. coli expression vector for the present invention.

Expression in Eukaryotes

A variety of eukaryotic expression systems such as yeast, insect celllines, plant and mammalian cells, are known to those of skill in theart. As explained briefly below, the present invention can be expressedin these eukaryotic systems. In some embodiments,transformed/transfected plant cells, as discussed infra, are employed asexpression systems for production of the proteins of the instantinvention.

Synthesis of heterologous proteins in yeast is well known. Sherman, etal., (1982) METHODS IN YEAST GENETICS, Cold Spring Harbor Laboratory isa well recognized work describing the various methods available toproduce the protein in yeast. Two widely utilized yeasts for productionof eukaryotic proteins are Saccharomyces cerevisiae and Pichia pastoris.Vectors, strains and protocols for expression in Saccharomyces andPichia are known in the art and available from commercial suppliers(e.g., Invitrogen). Suitable vectors usually have expression controlsequences, such as promoters, including 3-phosphoglycerate kinase oralcohol oxidase and an origin of replication, termination sequences andthe like as desired.

A protein of the present invention, once expressed, can be isolated fromyeast by lysing the cells and applying standard protein isolationtechniques to the lysates or the pellets. The monitoring of thepurification process can be accomplished by using Western blottechniques or radioimmunoassay of other standard immunoassay techniques.

The sequences encoding proteins of the present invention can also beligated to various expression vectors for use in transfecting cellcultures of, for instance, mammalian, insect or plant origin. Mammaliancell systems often will be in the form of monolayers of cells althoughmammalian cell suspensions may also be used. A number of suitable hostcell lines capable of expressing intact proteins have been developed inthe art, and include the HEK293, BHK21 and CHO cell lines. Expressionvectors for these cells can include expression control sequences, suchas an origin of replication, a promoter (e.g., the CMV promoter, a HSVtk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer(Queen, et al., (1986) Immunol. Rev. 89:49) and necessary processinginformation sites, such as ribosome binding sites, RNA splice sites,polyadenylation sites (e.g., an SV40 large T Ag poly A addition site)and transcriptional terminator sequences. Other animal cells useful forproduction of proteins of the present invention are available, forinstance, from the American Type Culture Collection Catalogue of CellLines and Hybridomas (7^(th) ed., 1992).

Appropriate vectors for expressing proteins of the present invention ininsect cells are usually derived from the SF9 baculovirus. Suitableinsect cell lines include mosquito larvae, silkworm, armyworm, moth andDrosophila cell lines such as a Schneider cell line (see, e.g.,Schneider, (1987) J. Embryol. Exp. Morphol. 27:353-65).

As with yeast, when higher animal or plant host cells are employed,polyadenlyation or transcription terminator sequences are typicallyincorporated into the vector. An example of a terminator sequence is thepolyadenlyation sequence from the bovine growth hormone gene. Sequencesfor accurate splicing of the transcript may also be included. An exampleof a splicing sequence is the VP1 intron from SV40 (Sprague, et al.,(1983) J. Virol. 45:773-81). Additionally, gene sequences to controlreplication in the host cell may be incorporated into the vector such asthose found in bovine papilloma virus type-vectors (Saveria-Campo,“Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector,” in DNACLONING: A PRACTICAL APPROACH, vol. II, Glover, ed., IRL Press,Arlington, Va., pp. 213-38 (1985)).

In addition, the gene for ARGOS placed in the appropriate plantexpression vector can be used to transform plant cells. The polypeptidecan then be isolated from plant callus or the transformed cells can beused to regenerate transgenic plants. Such transgenic plants can beharvested and the appropriate tissues (seed or leaves, for example) canbe subjected to large scale protein extraction and purificationtechniques.

Plant Transformation Methods

Numerous methods for introducing foreign genes into plants are known andcan be used to insert a ARGOS polynucleotide into a plant host,including biological and physical plant transformation protocols. See,e.g., Miki, et al., “Procedure for Introducing Foreign DNA into Plants,”in METHODS IN PLANT MOLECULAR BIOLOGY AND BIOTECHNOLOGY, Glick andThompson, eds., CRC Press, Inc., Boca Raton, pp. 67-88 (1993). Themethods chosen vary with the host plant, and include chemicaltransfection methods such as calcium phosphate, microorganism-mediatedgene transfer such as Agrobacterium (Horsch, et al., (1985) Science227:1229-31), electroporation, micro-injection and biolisticbombardment.

Expression cassettes and vectors and in vitro culture methods for plantcell or tissue transformation and regeneration of plants are known andavailable. See, e.g., Gruber, et al., “Vectors for PlantTransformation,” in METHODS IN PLANT MOLECULAR BIOLOGY ANDBIOTECHNOLOGY, supra, pp. 89-119.

The isolated polynucleotides or polypeptides may be introduced into theplant by one or more techniques typically used for direct delivery intocells. Such protocols may vary depending on the type of organism, cell,plant or plant cell, i.e., monocot or dicot, targeted for genemodification. Suitable methods of transforming plant cells includemicroinjection (Crossway, et al., (1986) Biotechniques 4:320-334 andU.S. Pat. No. 6,300,543), electroporation (Riggs, et al., (1986) Proc.Natl. Acad. Sci. USA 83:5602-5606, direct gene transfer (Paszkowski, etal., (1984) EMBO J. 3:2717-2722) and ballistic particle acceleration(see, for example, Sanford, et al., U.S. Pat. No. 4,945,050; WO1991/10725 and McCabe, et al., (1988) Biotechnology 6:923-926). Alsosee, Tomes, et al., Direct DNA Transfer into Intact Plant Cells ViaMicroprojectile Bombardment. pp. 197-213 in Plant Cell, Tissue and OrganCulture, Fundamental Methods eds. Gamborg and Phillips, Springer-VerlagBerlin Heidelberg N.Y., 1995; U.S. Pat. No. 5,736,369 (meristem);Weissinger, et al., (1988) Ann. Rev. Genet. 22:421-477; Sanford, et al.,(1987) Particulate Science and Technology 5:27-37 (onion); Christou, etal., (1988) Plant Physiol. 87:671-674 (soybean); Datta, et al., (1990)Biotechnology 8:736-740 (rice); Klein, et al., (1988) Proc. Natl. Acad.Sci. USA 85:4305-4309 (maize); Klein, et al., (1988) Biotechnology6:559-563 (maize); WO 1991/10725 (maize); Klein, et al., (1988) PlantPhysiol. 91:440-444 (maize); Fromm, et al., (1990) Biotechnology8:833-839 and Gordon-Kamm, et al., (1990) Plant Cell 2:603-618 (maize);Hooydaas-Van Slogteren and Hooykaas, (1984) Nature (London) 311:763-764;Bytebier, et al., (1987) Proc. Natl. Acad. Sci. USA 84:5345-5349(Liliaceae); De Wet, et al., (1985) In The Experimental Manipulation ofOvule Tissues, ed. Chapman, et al., pp. 197-209; Longman, N Y (pollen);Kaeppler, et al., (1990) Plant Cell Reports 9:415-418; and Kaeppler, etal., (1992) Theor. Appl. Genet. 84:560-566 (whisker-mediatedtransformation); U.S. Pat. No. 5,693,512 (sonication); D'Halluin, etal., (1992) Plant Cell 4:1495-1505 (electroporation); Li, et al., (1993)Plant Cell Reports 12:250-255 and Christou and Ford, (1995) Annals ofBotany 75:407-413 (rice); Osjoda, et al., (1996) Nature Biotech.14:745-750; Agrobacterium mediated maize transformation (U.S. Pat. No.5,981,840); silicon carbide whisker methods (Frame, et al., (1994) PlantJ. 6:941-948); laser methods (Guo, et al., (1995) Physiologia Plantarum93:19-24); sonication methods (Bao, et al., (1997) Ultrasound inMedicine & Biology 23:953-959; Finer and Finer, (2000) Lett ApplMicrobiol. 30:406-10; Amoah, et al., (2001) J Exp Bot 52:1135-42);polyethylene glycol methods (Krens, et al., (1982) Nature 296:72-77);protoplasts of monocot and dicot cells can be transformed usingelectroporation (Fromm, et al., (1985) Proc. Natl. Acad. Sci. USA82:5824-5828) and microinjection (Crossway, et al., (1986) Mol. Gen.Genet. 202:179-185), all of which are herein incorporated by reference.

Agrobacterium-Mediated Transformation

The most widely utilized method for introducing an expression vectorinto plants is based on the natural transformation system ofAgrobacterium. A. tumefaciens and A. rhizogenes are plant pathogenicsoil bacteria, which genetically transform plant cells. The Ti and Riplasmids of A. tumefaciens and A. rhizogenes, respectively, carry genesresponsible for genetic transformation of plants. See, e.g., Kado,(1991) Crit. Rev. Plant Sci. 10:1. Descriptions of the Agrobacteriumvector systems and methods for Agrobacterium-mediated gene transfer areprovided in Gruber, et al., supra; Miki, et al., supra and Moloney, etal., (1989) Plant Cell Reports 8:238.

Similarly, the gene can be inserted into the T-DNA region of a Ti or Riplasmid derived from A. tumefaciens or A. rhizogenes, respectively.Thus, expression cassettes can be constructed as above, using theseplasmids. Many control sequences are known which when coupled to aheterologous coding sequence and transformed into a host organism showfidelity in gene expression with respect to tissue/organ specificity ofthe original coding sequence. See, e.g., Benfey and Chua, (1989) Science244:174-81. Particularly suitable control sequences for use in theseplasmids are promoters for constitutive leaf-specific expression of thegene in the various target plants. Other useful control sequencesinclude a promoter and terminator from the nopaline synthase gene (NOS).The NOS promoter and terminator are present in the plasmid pARC2,available from the American Type Culture Collection and designated ATCC67238. If such a system is used, the virulence (vir) gene from eitherthe Ti or Ri plasmid must also be present, either along with the T-DNAportion, or via a binary system where the vir gene is present on aseparate vector. Such systems, vectors for use therein, and methods oftransforming plant cells are described in U.S. Pat. No. 4,658,082; U.S.Pat. No. 913,914, filed Oct. 1, 1986, as referenced in U.S. Pat. No.5,262,306, issued Nov. 16, 1993 and Simpson, et al., (1986) Plant Mol.Biol. 6:403-15 (also referenced in the '306 patent), all incorporated byreference in their entirety.

Once constructed, these plasmids can be placed into A. rhizogenes or A.tumefaciens and these vectors used to transform cells of plant species,which are ordinarily susceptible to Fusarium or Alternaria infection.Several other transgenic plants are also contemplated by the presentinvention including but not limited to soybean, corn, sorghum, alfalfa,rice, clover, cabbage, banana, coffee, celery, tobacco, cowpea, cotton,melon and pepper. The selection of either A. tumefaciens or A.rhizogenes will depend on the plant being transformed thereby. Ingeneral A. tumefaciens is the preferred organism for transformation.Most dicotyledonous plants, some gymnosperms and a few monocotyledonousplants (e.g., certain members of the Liliales and Arales) aresusceptible to infection with A. tumefaciens. A. rhizogenes also has awide host range, embracing most dicots and some gymnosperms, whichincludes members of the Leguminosae, Compositae, and Chenopodiaceae.Monocot plants can now be transformed with some success. EP PatentApplication Number 604 662 A1 discloses a method for transformingmonocots using Agrobacterium. EP Patent Application Number 672 752 A1discloses a method for transforming monocots with Agrobacterium usingthe scutellum of immature embryos. Ishida, et al., discuss a method fortransforming maize by exposing immature embryos to A. tumefaciens(Nature Biotechnology 14:745-50 (1996)).

Once transformed, these cells can be used to regenerate transgenicplants. For example, whole plants can be infected with these vectors bywounding the plant and then introducing the vector into the wound site.Any part of the plant can be wounded, including leaves, stems and roots.Alternatively, plant tissue, in the form of an explant, such ascotyledonary tissue or leaf disks, can be inoculated with these vectors,and cultured under conditions, which promote plant regeneration. Rootsor shoots transformed by inoculation of plant tissue with A. rhizogenesor A. tumefaciens, containing the gene coding for the fumonisindegradation enzyme, can be used as a source of plant tissue toregenerate fumonisin-resistant transgenic plants, either via somaticembryogenesis or organogenesis. Examples of such methods forregenerating plant tissue are disclosed in Shahin, (1985) Theor. Appl.Genet. 69:235-40; U.S. Pat. No. 4,658,082; Simpson, et al., supra; andU.S. Pat. No. 913,913 and 913,914, both filed Oct. 1, 1986, asreferenced in U.S. Pat. No. 5,262,306, issued Nov. 16, 1993, the entiredisclosures therein incorporated herein by reference.

Direct Gene Transfer

Despite the fact that the host range for Agrobacterium-mediatedtransformation is broad, some major cereal crop species and gymnospermshave generally been recalcitrant to this mode of gene transfer, eventhough some success has recently been achieved in rice (Hiei, et al.,(1994) The Plant Journal 6:271-82). Several methods of planttransformation, collectively referred to as direct gene transfer, havebeen developed as an alternative to Agrobacterium-mediatedtransformation.

A generally applicable method of plant transformation ismicroprojectile-mediated transformation, where DNA is carried on thesurface of microprojectiles measuring about 1 to 4 μm. The expressionvector is introduced into plant tissues with a biolistic device thataccelerates the microprojectiles to speeds of 300 to 600 m/s which issufficient to penetrate the plant cell walls and membranes (Sanford, etal., (1987) Part. Sci. Technol. 5:27; Sanford, (1988) Trends Biotech6:299; Sanford, (1990) Physiol. Plant 79:206 and Klein, et al., (1992)Biotechnology 10:268).

Another method for physical delivery of DNA to plants is sonication oftarget cells as described in Zang, et al., (1991) BioTechnology 9:996.Alternatively, liposome or spheroplast fusions have been used tointroduce expression vectors into plants. See, e.g., Deshayes, et al.,(1985) EMBO J. 4:2731 and Christou, et al., (1987) Proc. Natl. Acad.Sci. USA 84:3962. Direct uptake of DNA into protoplasts using CaCl₂precipitation, polyvinyl alcohol, or poly-L-ornithine has also beenreported. See, e.g., Hain, et al., (1985) Mol. Gen. Genet. 199:161 andDraper, et al., (1982) Plant Cell Physiol. 23:451.

Electroporation of protoplasts and whole cells and tissues has also beendescribed. See, e.g., Donn, et al., (1990) in Abstracts of the VIIthInt'l. Congress on Plant Cell and Tissue Culture IAPTC, A2-38, p. 53;D'Halluin, et al., (1992) Plant Cell 4:1495-505 and Spencer, et al.,(1994) Plant Mol. Biol. 24:51-61.

Increasing the Activity and/or Level of a ARGOS Polypeptide

Methods are provided to increase the activity and/or level of the ARGOSpolypeptide of the invention. An increase in the level and/or activityof the ARGOS polypeptide of the invention can be achieved by providingto the plant an ARGOS polypeptide. The ARGOS polypeptide can be providedby introducing the amino acid sequence encoding the ARGOS polypeptideinto the plant, introducing into the plant a nucleotide sequenceencoding an ARGOS polypeptide or alternatively by modifying a genomiclocus encoding the ARGOS polypeptide of the invention. As discussedelsewhere herein, many methods are known the art for providing apolypeptide to a plant including, but not limited to, directintroduction of the polypeptide into the plant, introducing into theplant (transiently or stably) a polynucleotide construct encoding apolypeptide having cell number regulator activity. It is also recognizedthat the methods of the invention may employ a polynucleotide that isnot capable of directing, in the transformed plant, the expression of aprotein or an RNA. Thus, the level and/or activity of an ARGOSpolypeptide may be increased by altering the gene encoding the ARGOSpolypeptide or its promoter. See, e.g., Kmiec, U.S. Pat. No. 5,565,350;Zarling, et al., PCT/US93/03868. Therefore mutagenized plants that carrymutations in ARGOS genes, where the mutations increase expression of theARGOS gene or increase the plant growth and/or organ developmentactivity of the encoded ARGOS polypeptide are provided.

Reducing the Activity and/or Level of a ARGOS Polypeptide

Methods are provided to reduce or eliminate the activity of an ARGOSpolypeptide of the invention by transforming a plant cell with anexpression cassette that expresses a polynucleotide that inhibits theexpression of the ARGOS polypeptide. The polynucleotide may inhibit theexpression of the ARGOS polypeptide directly, by preventing translationof the ARGOS messenger RNA, or indirectly, by encoding a polypeptidethat inhibits the transcription or translation of a ARGOS gene encodinga ARGOS polypeptide. Methods for inhibiting or eliminating theexpression of a gene in a plant are well known in the art, and any suchmethod may be used in the present invention to inhibit the expression ofan ARGOS polypeptide.

In accordance with the present invention, the expression of a ARGOSpolypeptide is inhibited if the protein level of the ARGOS polypeptideis less than 70% of the protein level of the same ARGOS polypeptide in aplant that has not been genetically modified or mutagenized to inhibitthe expression of that ARGOS polypeptide. In particular embodiments ofthe invention, the protein level of the ARGOS polypeptide in a modifiedplant according to the invention is less than 60%, less than 50%, lessthan 40%, less than 30%, less than 20%, less than 10%, less than 5% orless than 2% of the protein level of the same ARGOS polypeptide in aplant that is not a mutant or that has not been genetically modified toinhibit the expression of that ARGOS polypeptide. The expression levelof the ARGOS polypeptide may be measured directly, for example, byassaying for the level of ARGOS polypeptide expressed in the plant cellor plant, or indirectly, for example, by measuring the plant growthand/or organ development activity of the ARGOS polypeptide in the plantcell or plant or by measuring the biomass in the plant. Methods forperforming such assays are described elsewhere herein.

In other embodiments of the invention, the activity of the ARGOSpolypeptides is reduced or eliminated by transforming a plant cell withan expression cassette comprising a polynucleotide encoding apolypeptide that inhibits the activity of a ARGOS polypeptide. The plantgrowth and/or organ development activity of a ARGOS polypeptide isinhibited according to the present invention if the plant growth and/ororgan development activity of the ARGOS polypeptide is less than 70% ofthe plant growth and/or organ development activity of the same ARGOSpolypeptide in a plant that has not been modified to inhibit the plantgrowth and/or organ development activity of that ARGOS polypeptide. Inparticular embodiments of the invention, the plant growth and/or organdevelopment activity of the ARGOS polypeptide in a modified plantaccording to the invention is less than 60%, less than 50%, less than40%, less than 30%, less than 20%, less than 10% or less than 5% of theplant growth and/or organ development activity of the same ARGOSpolypeptide in a plant that that has not been modified to inhibit theexpression of that ARGOS polypeptide. The plant growth and/or organdevelopment activity of an ARGOS polypeptide is “eliminated” accordingto the invention when it is not detectable by the assay methodsdescribed elsewhere herein. Methods of determining the plant growthand/or organ development activity of an ARGOS polypeptide are describedelsewhere herein.

In other embodiments, the activity of an ARGOS polypeptide may bereduced or eliminated by disrupting the gene encoding the ARGOSpolypeptide. The invention encompasses mutagenized plants that carrymutations in ARGOS genes, where the mutations reduce expression of theARGOS gene or inhibit the plant growth and/or organ development activityof the encoded ARGOS polypeptide.

Thus, many methods may be used to reduce or eliminate the activity of anARGOS polypeptide. In addition, more than one method may be used toreduce the activity of a single ARGOS polypeptide. Non-limiting examplesof methods of reducing or eliminating the expression of ARGOSpolypeptides are given below.

1. Polynucleotide-Based Methods:

In some embodiments of the present invention, a plant is transformedwith an expression cassette that is capable of expressing apolynucleotide that inhibits the expression of an ARGOS polypeptide ofthe invention. The term “expression” as used herein refers to thebiosynthesis of a gene product, including the transcription and/ortranslation of said gene product. For example, for the purposes of thepresent invention, an expression cassette capable of expressing apolynucleotide that inhibits the expression of at least one ARGOSpolypeptide is an expression cassette capable of producing an RNAmolecule that inhibits the transcription and/or translation of at leastone ARGOS polypeptide of the invention. The “expression” or “production”of a protein or polypeptide from a DNA molecule refers to thetranscription and translation of the coding sequence to produce theprotein or polypeptide, while the “expression” or “production” of aprotein or polypeptide from an RNA molecule refers to the translation ofthe RNA coding sequence to produce the protein or polypeptide.

Examples of polynucleotides that inhibit the expression of an ARGOSpolypeptide are given below.

i. Sense Suppression/Cosuppression

In some embodiments of the invention, inhibition of the expression of aARGOS polypeptide may be obtained by sense suppression or cosuppression.For cosuppression, an expression cassette is designed to express an RNAmolecule corresponding to all or part of a messenger RNA encoding anARGOS polypeptide in the “sense” orientation. Over expression of the RNAmolecule can result in reduced expression of the native gene.Accordingly, multiple plant lines transformed with the cosuppressionexpression cassette are screened to identify those that show thegreatest inhibition of ARGOS polypeptide expression.

The polynucleotide used for cosuppression may correspond to all or partof the sequence encoding the ARGOS polypeptide, all or part of the 5′and/or 3′ untranslated region of an ARGOS polypeptide transcript or allor part of both the coding sequence and the untranslated regions of atranscript encoding an ARGOS polypeptide. In some embodiments where thepolynucleotide comprises all or part of the coding region for the ARGOSpolypeptide, the expression cassette is designed to eliminate the startcodon of the polynucleotide so that no protein product will betranslated.

Cosuppression may be used to inhibit the expression of plant genes toproduce plants having undetectable protein levels for the proteinsencoded by these genes. See, for example, Broin, et al., (2002) PlantCell 14:1417-1432. Cosuppression may also be used to inhibit theexpression of multiple proteins in the same plant. See, for example,U.S. Pat. No. 5,942,657. Methods for using cosuppression to inhibit theexpression of endogenous genes in plants are described in Flavell, etal., (1994) Proc. Natl. Acad. Sci. USA 91:3490-3496; Jorgensen, et al.,(1996) Plant Mol. Biol. 31:957-973; Johansen and Carrington, (2001)Plant Physiol. 126:930-938; Broin, et al., (2002) Plant Cell14:1417-1432; Stoutjesdijk, et al., (2002) Plant Physiol. 129:1723-1731;Yu, et al., (2003) Phytochemistry 63:753-763 and U.S. Pat. Nos.5,034,323, 5,283,184 and 5,942,657, each of which is herein incorporatedby reference. The efficiency of cosuppression may be increased byincluding a poly-dT region in the expression cassette at a position 3′to the sense sequence and 5′ of the polyadenylation signal. See, USPatent Application Publication Number 2002/0048814, herein incorporatedby reference. Typically, such a nucleotide sequence has substantialsequence identity to the sequence of the transcript of the endogenousgene, optimally greater than about 65% sequence identity, more optimallygreater than about 85% sequence identity, most optimally greater thanabout 95% sequence identity. See U.S. Pat. Nos. 5,283,184 and 5,034,323,herein incorporated by reference.

ii. Antisense Suppression

In some embodiments of the invention, inhibition of the expression ofthe ARGOS polypeptide may be obtained by antisense suppression. Forantisense suppression, the expression cassette is designed to express anRNA molecule complementary to all or part of a messenger RNA encodingthe ARGOS polypeptide. Over expression of the antisense RNA molecule canresult in reduced expression of the native gene. Accordingly, multipleplant lines transformed with the antisense suppression expressioncassette are screened to identify those that show the greatestinhibition of ARGOS polypeptide expression.

The polynucleotide for use in antisense suppression may correspond toall or part of the complement of the sequence encoding the ARGOSpolypeptide, all or part of the complement of the 5′ and/or 3′untranslated region of the ARGOS transcript or all or part of thecomplement of both the coding sequence and the untranslated regions of atranscript encoding the ARGOS polypeptide. In addition, the antisensepolynucleotide may be fully complementary (i.e., 100% identical to thecomplement of the target sequence) or partially complementary (i.e.,less than 100% identical to the complement of the target sequence) tothe target sequence. Antisense suppression may be used to inhibit theexpression of multiple proteins in the same plant. See, for example,U.S. Pat. No. 5,942,657. Furthermore, portions of the antisensenucleotides may be used to disrupt the expression of the target gene.Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200nucleotides, 300, 400, 450, 500, 550 or greater may be used. Methods forusing antisense suppression to inhibit the expression of endogenousgenes in plants are described, for example, in Liu, et al., (2002) PlantPhysiol. 129:1732-1743 and U.S. Pat. Nos. 5,759,829 and 5,942,657, eachof which is herein incorporated by reference. Efficiency of antisensesuppression may be increased by including a poly-dT region in theexpression cassette at a position 3′ to the antisense sequence and 5′ ofthe polyadenylation signal. See, US Patent Application PublicationNumber 2002/0048814, herein incorporated by reference.

iii. Double-Stranded RNA Interference

In some embodiments of the invention, inhibition of the expression of aARGOS polypeptide may be obtained by double-stranded RNA (dsRNA)interference. For dsRNA interference, a sense RNA molecule like thatdescribed above for cosuppression and an antisense RNA molecule that isfully or partially complementary to the sense RNA molecule are expressedin the same cell, resulting in inhibition of the expression of thecorresponding endogenous messenger RNA.

Expression of the sense and antisense molecules can be accomplished bydesigning the expression cassette to comprise both a sense sequence andan antisense sequence. Alternatively, separate expression cassettes maybe used for the sense and antisense sequences. Multiple plant linestransformed with the dsRNA interference expression cassette orexpression cassettes are then screened to identify plant lines that showthe greatest inhibition of ARGOS polypeptide expression. Methods forusing dsRNA interference to inhibit the expression of endogenous plantgenes are described in Waterhouse, et al., (1998) Proc. Natl. Acad. Sci.USA 95:13959-13964, Liu, et al., (2002) Plant Physiol. 129:1732-1743,and WO 1999/49029, WO 1999/53050, WO 1999/61631 and WO 2000/49035, eachof which is herein incorporated by reference.

iv. Hairpin RNA Interference and Intron-Containing Hairpin RNAInterference

In some embodiments of the invention, inhibition of the expression ofone or a ARGOS polypeptide may be obtained by hairpin RNA (hpRNA)interference or intron-containing hairpin RNA (ihpRNA) interference.These methods are highly efficient at inhibiting the expression ofendogenous genes. See, Waterhouse and Helliwell, (2003) Nat. Rev. Genet.4:29-38 and the references cited therein.

For hpRNA interference, the expression cassette is designed to expressan RNA molecule that hybridizes with itself to form a hairpin structurethat comprises a single-stranded loop region and a base-paired stem. Thebase-paired stem region comprises a sense sequence corresponding to allor part of the endogenous messenger RNA encoding the gene whoseexpression is to be inhibited and an antisense sequence that is fully orpartially complementary to the sense sequence. Thus, the base-pairedstem region of the molecule generally determines the specificity of theRNA interference. hpRNA molecules are highly efficient at inhibiting theexpression of endogenous genes, and the RNA interference they induce isinherited by subsequent generations of plants. See, for example, Chuangand Meyerowitz, (2000) Proc. Natl. Acad. Sci. USA 97:4985-4990;Stoutjesdijk, et al., (2002) Plant Physiol. 129:1723-1731 and Waterhouseand Helliwell, (2003) Nat. Rev. Genet. 4:29-38. Methods for using hpRNAinterference to inhibit or silence the expression of genes aredescribed, for example, in Chuang and Meyerowitz, (2000) Proc. Natl.Acad. Sci. USA 97:4985-4990; Stoutjesdijk, et al., (2002) Plant Physiol.129:1723-1731; Waterhouse and Helliwell, (2003) Nat. Rev. Genet.4:29-38; Pandolfini, et al., BMC Biotechnology 3:7 and US PatentApplication Publication Number 2003/0175965, each of which is hereinincorporated by reference. A transient assay for the efficiency of hpRNAconstructs to silence gene expression in vivo has been described byPanstruga, et al., (2003) Mol. Biol. Rep. 30:135-140, hereinincorporated by reference.

For ihpRNA, the interfering molecules have the same general structure asfor hpRNA, but the RNA molecule additionally comprises an intron that iscapable of being spliced in the cell in which the ihpRNA is expressed.The use of an intron minimizes the size of the loop in the hairpin RNAmolecule following splicing and this increases the efficiency ofinterference. See, for example, Smith, et al., (2000) Nature407:319-320. In fact, Smith, et al., show 100% suppression of endogenousgene expression using ihpRNA-mediated interference. Methods for usingihpRNA interference to inhibit the expression of endogenous plant genesare described, for example, in Smith, et al., (2000) Nature 407:319-320;Wesley, et al., (2001) Plant J. 27:581-590; Wang and Waterhouse, (2001)Curr. Opin. Plant Biol. 5:146-150; Waterhouse and Helliwell, (2003) Nat.Rev. Genet. 4:29-38; Helliwell and Waterhouse, (2003) Methods 30:289-295and US Patent Application Publication Number 2003/0180945, each of whichis herein incorporated by reference.

The expression cassette for hpRNA interference may also be designed suchthat the sense sequence and the antisense sequence do not correspond toan endogenous RNA. In this embodiment, the sense and antisense sequenceflank a loop sequence that comprises a nucleotide sequence correspondingto all or part of the endogenous messenger RNA of the target gene. Thus,it is the loop region that determines the specificity of the RNAinterference. See, for example, WO 2002/00904, herein incorporated byreference.

v. Amplicon-Mediated Interference

Amplicon expression cassettes comprise a plant virus-derived sequencethat contains all or part of the target gene but generally not all ofthe genes of the native virus. The viral sequences present in thetranscription product of the expression cassette allow the transcriptionproduct to direct its own replication. The transcripts produced by theamplicon may be either sense or antisense relative to the targetsequence (i.e., the messenger RNA for the ARGOS polypeptide). Methods ofusing amplicons to inhibit the expression of endogenous plant genes aredescribed, for example, in Angell and Baulcombe, (1997) EMBO J.16:3675-3684, Angell and Baulcombe, (1999) Plant J. 20:357-362 and U.S.Pat. No. 6,646,805, each of which is herein incorporated by reference.

vi. Ribozymes

In some embodiments, the polynucleotide expressed by the expressioncassette of the invention is catalytic RNA or has ribozyme activityspecific for the messenger RNA of the ARGOS polypeptide. Thus, thepolynucleotide causes the degradation of the endogenous messenger RNA,resulting in reduced expression of the ARGOS polypeptide. This method isdescribed, for example, in U.S. Pat. No. 4,987,071, herein incorporatedby reference.

vii. Small Interfering RNA or Micro RNA

In some embodiments of the invention, inhibition of the expression of aARGOS polypeptide may be obtained by RNA interference by expression of agene encoding a micro RNA (miRNA). miRNAs are regulatory agentsconsisting of about 22 ribonucleotides. miRNA are highly efficient atinhibiting the expression of endogenous genes. See, for example, Javier,et al., (2003) Nature 425:257-263, herein incorporated by reference.

For miRNA interference, the expression cassette is designed to expressan RNA molecule that is modeled on an endogenous miRNA gene. The miRNAgene encodes an RNA that forms a hairpin structure containing a22-nucleotide sequence that is complementary to another endogenous gene(target sequence). For suppression of ARGOS expression, the22-nucleotide sequence is selected from a ARGOS transcript sequence andcontains 22 nucleotides of said ARGOS sequence in sense orientation and21 nucleotides of a corresponding antisense sequence that iscomplementary to the sense sequence. miRNA molecules are highlyefficient at inhibiting the expression of endogenous genes and the RNAinterference they induce is inherited by subsequent generations ofplants.

2. Polypeptide-Based Inhibition of Gene Expression

In one embodiment, the polynucleotide encodes a zinc finger protein thatbinds to a gene encoding an ARGOS polypeptide, resulting in reducedexpression of the gene. In particular embodiments, the zinc fingerprotein binds to a regulatory region of an ARGOS gene. In otherembodiments, the zinc finger protein binds to a messenger RNA encodingan ARGOS polypeptide and prevents its translation. Methods of selectingsites for targeting by zinc finger proteins have been described, forexample, in U.S. Pat. No. 6,453,242 and methods for using zinc fingerproteins to inhibit the expression of genes in plants are described, forexample, in US Patent Application Publication Number 2003/0037355, eachof which is herein incorporated by reference.

3. Polypeptide-Based Inhibition of Protein Activity

In some embodiments of the invention, the polynucleotide encodes anantibody that binds to at least one ARGOS polypeptide and reduces thecell number regulator activity of the ARGOS polypeptide. In anotherembodiment, the binding of the antibody results in increased turnover ofthe antibody-ARGOS complex by cellular quality control mechanisms. Theexpression of antibodies in plant cells and the inhibition of molecularpathways by expression and binding of antibodies to proteins in plantcells are well known in the art. See, for example, Conrad and Sonnewald,(2003) Nature Biotech. 21:35-36, incorporated herein by reference.

4. Gene Disruption

In some embodiments of the present invention, the activity of an ARGOSpolypeptide is reduced or eliminated by disrupting the gene encoding theARGOS polypeptide. The gene encoding the ARGOS polypeptide may bedisrupted by any method known in the art. For example, in oneembodiment, the gene is disrupted by transposon tagging. In anotherembodiment, the gene is disrupted by mutagenizing plants using random ortargeted mutagenesis and selecting for plants that have reduced cellnumber regulator activity.

i. Transposon Tagging

In one embodiment of the invention, transposon tagging is used to reduceor eliminate the ARGOS activity of one or more ARGOS polypeptide.Transposon tagging comprises inserting a transposon within an endogenousARGOS gene to reduce or eliminate expression of the ARGOS polypeptide.“ARGOS gene” is intended to mean the gene that encodes an ARGOSpolypeptide according to the invention.

In this embodiment, the expression of one or more ARGOS polypeptide isreduced or eliminated by inserting a transposon within a regulatoryregion or coding region of the gene encoding the ARGOS polypeptide. Atransposon that is within an exon, intron, 5′ or 3′ untranslatedsequence, a promoter or any other regulatory sequence of a ARGOS genemay be used to reduce or eliminate the expression and/or activity of theencoded ARGOS polypeptide.

Methods for the transposon tagging of specific genes in plants are wellknown in the art. See, for example, Maes, et al., (1999) Trends PlantSci. 4:90-96; Dharmapuri and Sonti, (1999) FEMS Microbiol. Lett.179:53-59; Meissner, et al., (2000) Plant J. 22:265-274; Phogat, et al.,(2000) J. Biosci. 25:57-63; Walbot, (2000) Curr. Opin. Plant Biol.2:103-107; Gai, et al., (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice,et al., (1999) Genetics 153:1919-1928). In addition, the TUSC processfor selecting Mu insertions in selected genes has been described inBensen, et al., (1995) Plant Cell 7:75-84; Mena, et al., (1996) Science274:1537-1540 and U.S. Pat. No. 5,962,764, each of which is hereinincorporated by reference.

ii. Mutant Plants with Reduced Activity

Additional methods for decreasing or eliminating the expression ofendogenous genes in plants are also known in the art and can besimilarly applied to the instant invention. These methods include otherforms of mutagenesis, such as ethyl methanesulfonate-inducedmutagenesis, deletion mutagenesis and fast neutron deletion mutagenesisused in a reverse genetics sense (with PCR) to identify plant lines inwhich the endogenous gene has been deleted. For examples of thesemethods see, Ohshima, et al., (1998) Virology 243:472-481; Okubara, etal., (1994) Genetics 137:867-874 and Quesada, et al., (2000) Genetics154:421-436, each of which is herein incorporated by reference. Inaddition, a fast and automatable method for screening for chemicallyinduced mutations, TILLING (Targeting Induced Local Lesions In Genomes),using denaturing HPLC or selective endonuclease digestion of selectedPCR products is also applicable to the instant invention. See, McCallum,et al., (2000) Nat. Biotechnol. 18:455-457, herein incorporated byreference.

Mutations that impact gene expression or that interfere with thefunction (cell number regulator activity) of the encoded protein arewell known in the art. Insertional mutations in gene exons usuallyresult in null-mutants. Mutations in conserved residues are particularlyeffective in inhibiting the cell number regulator activity of theencoded protein. Conserved residues of plant ARGOS polypeptides suitablefor mutagenesis with the goal to eliminate cell number regulatoractivity have been described. Such mutants can be isolated according towell-known procedures and mutations in different ARGOS loci can bestacked by genetic crossing. See, for example, Gruis, et al., (2002)Plant Cell 14:2863-2882.

In another embodiment of this invention, dominant mutants can be used totrigger RNA silencing due to gene inversion and recombination of aduplicated gene locus. See, for example, Kusaba, et al., (2003) PlantCell 15:1455-1467.

The invention encompasses additional methods for reducing or eliminatingthe activity of one or more ARGOS polypeptide. Examples of other methodsfor altering or mutating a genomic nucleotide sequence in a plant areknown in the art and include, but are not limited to, the use of RNA:DNAvectors, RNA:DNA mutational vectors, RNA:DNA repair vectors,mixed-duplex oligonucleotides, self-complementary RNA:DNAoligonucleotides and recombinogenic oligonucleobases. Such vectors andmethods of use are known in the art. See, for example, U.S. Pat. Nos.5,565,350; 5,731,181; 5,756,325; 5,760,012; 5,795,972 and 5,871,984,each of which are herein incorporated by reference. See also, WO1998/49350, WO 1999/07865, WO 1999/25821 and Beetham, et al., (1999)Proc. Natl. Acad. Sci. USA 96:8774-8778, each of which is hereinincorporated by reference.

iii. Modulating Plant Growth and/or Organ Development Activity

In specific methods, the level and/or activity of a cell numberregulator in a plant is increased by increasing the level or activity ofthe ARGOS polypeptide in the plant. Methods for increasing the leveland/or activity of ARGOS polypeptides in a plant are discussed elsewhereherein. Briefly, such methods comprise providing a ARGOS polypeptide ofthe invention to a plant and thereby increasing the level and/oractivity of the ARGOS polypeptide. In other embodiments, an ARGOSnucleotide sequence encoding an ARGOS polypeptide can be provided byintroducing into the plant a polynucleotide comprising an ARGOSnucleotide sequence of the invention, expressing the ARGOS sequence,increasing the activity of the ARGOS polypeptide and thereby increasingthe number of tissue cells in the plant or plant part. In otherembodiments, the ARGOS nucleotide construct introduced into the plant isstably incorporated into the genome of the plant.

In other methods, the number of cells and biomass of a plant tissue isinreased by increasing the level and/or activity of the ARGOSpolypeptide in the plant. Such methods are disclosed in detail elsewhereherein. In one such method, an ARGOS nucleotide sequence is introducedinto the plant and expression of said ARGOS nucleotide sequencedecreases the activity of the ARGOS polypeptide and thereby increasingthe plant growth and/or organ development in the plant or plant part. Inother embodiments, the ARGOS nucleotide construct introduced into theplant is stably incorporated into the genome of the plant.

As discussed above, one of skill will recognize the appropriate promoterto use to modulate the level/activity of a plant growth and/or organdevelopment polynucleotide and polypeptide in the plant. Exemplarypromoters for this embodiment have been disclosed elsewhere herein.

Accordingly, the present invention further provides plants having amodified plant growth and/or organ development when compared to theplant growth and/or organ development of a control plant tissue. In oneembodiment, the plant of the invention has an increased level/activityof the ARGOS polypeptide of the invention and thus has increased plantgrowth and/or organ development in the plant tissue. In otherembodiments, the plant of the invention has a reduced or eliminatedlevel of the ARGOS polypeptide of the invention and thus has decreasedplant growth and/or organ development in the plant tissue. In otherembodiments, such plants have stably incorporated into their genome anucleic acid molecule comprising a ARGOS nucleotide sequence of theinvention operably linked to a promoter that drives expression in theplant cell.

iv. Modulating Root Development

Methods for modulating root development in a plant are provided. By“modulating root development” is intended any alteration in thedevelopment of the plant root when compared to a control plant. Suchalterations in root development include, but are not limited to,alterations in the growth rate of the primary root, the fresh rootweight, the extent of lateral and adventitious root formation, thevasculature system, meristem development or radial expansion.

Methods for modulating root development in a plant are provided. Themethods comprise modulating the level and/or activity of the ARGOSpolypeptide in the plant. In one method, an ARGOS sequence of theinvention is provided to the plant. In another method, the ARGOSnucleotide sequence is provided by introducing into the plant apolynucleotide comprising an ARGOS nucleotide sequence of the invention,expressing the ARGOS sequence and thereby modifying root development. Instill other methods, the ARGOS nucleotide construct introduced into theplant is stably incorporated into the genome of the plant.

In other methods, root development is modulated by altering the level oractivity of the ARGOS polypeptide in the plant. An increase in ARGOSactivity can result in at least one or more of the following alterationsto root development, including, but not limited to, larger rootmeristems, increased in root growth, enhanced radial expansion, anenhanced vasculature system, increased root branching, more adventitiousroots and/or an increase in fresh root weight when compared to a controlplant.

As used herein, “root growth” encompasses all aspects of growth of thedifferent parts that make up the root system at different stages of itsdevelopment in both monocotyledonous and dicotyledonous plants. It is tobe understood that enhanced root growth can result from enhanced growthof one or more of its parts including the primary root, lateral roots,adventitious roots, etc.

Methods of measuring such developmental alterations in the root systemare known in the art. See, for example, US Patent ApplicationPublication Number 2003/0074698 and Werner, et al., (2001) PNAS18:10487-10492, both of which are herein incorporated by reference.

As discussed above, one of skill will recognize the appropriate promoterto use to modulate root development in the plant. Exemplary promotersfor this embodiment include constitutive promoters and root-preferredpromoters. Exemplary root-preferred promoters have been disclosedelsewhere herein.

Stimulating root growth and increasing root mass by increasing theactivity and/or level of the ARGOS polypeptide also finds use inimproving the standability of a plant. The term “resistance to lodging”or “standability” refers to the ability of a plant to fix itself to thesoil. For plants with an erect or semi-erect growth habit, this termalso refers to the ability to maintain an upright position under adverse(environmental) conditions. This trait relates to the size, depth andmorphology of the root system. In addition, stimulating root growth andincreasing root mass by increasing the level and/or activity of theARGOS polypeptide also finds use in promoting in vitro propagation ofexplants.

Furthermore, higher root biomass production due to an increased leveland/or activity of ARGOS activity has a direct effect on the yield andan indirect effect of production of compounds produced by root cells ortransgenic root cells or cell cultures of said transgenic root cells.One example of an interesting compound produced in root cultures isshikonin, the yield of which can be advantageously enhanced by saidmethods.

Accordingly, the present invention further provides plants havingmodulated root development when compared to the root development of acontrol plant. In some embodiments, the plant of the invention has anincreased level/activity of the ARGOS polypeptide of the invention andhas enhanced root growth and/or root biomass. In other embodiments, suchplants have stably incorporated into their genome a nucleic acidmolecule comprising a ARGOS nucleotide sequence of the inventionoperably linked to a promoter that drives expression in the plant cell.

v. Modulating Shoot and Leaf Development

Methods are also provided for modulating shoot and leaf development in aplant. By “modulating shoot and/or leaf development” is intended anyalteration in the development of the plant shoot and/or leaf. Suchalterations in shoot and/or leaf development include, but are notlimited to, alterations in shoot meristem development, in leaf number,leaf size, leaf and stem vasculature, internode length and leafsenescence. As used herein, “leaf development” and “shoot development”encompasses all aspects of growth of the different parts that make upthe leaf system and the shoot system, respectively, at different stagesof their development, both in monocotyledonous and dicotyledonousplants. Methods for measuring such developmental alterations in theshoot and leaf system are known in the art. See, for example, Werner, etal., (2001) PNAS 98:10487-10492 and US Patent Application PublicationNumber 2003/0074698, each of which is herein incorporated by reference.

The method for modulating shoot and/or leaf development in a plantcomprises modulating the activity and/or level of an ARGOS polypeptideof the invention. In one embodiment, an ARGOS sequence of the inventionis provided. In other embodiments, the ARGOS nucleotide sequence can beprovided by introducing into the plant a polynucleotide comprising anARGOS nucleotide sequence of the invention, expressing the ARGOSsequence and thereby modifying shoot and/or leaf development. In otherembodiments, the ARGOS nucleotide construct introduced into the plant isstably incorporated into the genome of the plant.

In specific embodiments, shoot or leaf development is modulated bydecreasing the level and/or activity of the ARGOS polypeptide in theplant. An decrease in ARGOS activity can result in at least one or moreof the following alterations in shoot and/or leaf development,including, but not limited to, reduced leaf number, reduced leafsurface, reduced vascular, shorter internodes and stunted growth andretarded leaf senescence, when compared to a control plant.

As discussed above, one of skill will recognize the appropriate promoterto use to modulate shoot and leaf development of the plant. Exemplarypromoters for this embodiment include constitutive promoters,shoot-preferred promoters, shoot meristem-pref erred promoters andleaf-preferred promoters. Exemplary promoters have been disclosedelsewhere herein.

Decreasing ARGOS activity and/or level in a plant results in shorterinternodes and stunted growth. Thus, the methods of the invention finduse in producing dwarf plants. In addition, as discussed above,modulation of ARGOS activity in the plant modulates both root and shootgrowth. Thus, the present invention further provides methods foraltering the root/shoot ratio. Shoot or leaf development can further bemodulated by decreasing the level and/or activity of the ARGOSpolypeptide in the plant.

Accordingly, the present invention further provides plants havingmodulated shoot and/or leaf development when compared to a controlplant. In some embodiments, the plant of the invention has an increasedlevel/activity of the ARGOS polypeptide of the invention, altering theshoot and/or leaf development. Such alterations include, but are notlimited to, increased leaf number, increased leaf surface, increasedvascularity, longer internodes and increased plant stature, as well asalterations in leaf senescence, as compared to a control plant. In otherembodiments, the plant of the invention has a decreased level/activityof the ARGOS polypeptide of the invention.

vi Modulating Reproductive Tissue Development

Methods for modulating reproductive tissue development are provided. Inone embodiment, methods are provided to modulate floral development in aplant. By “modulating floral development” is intended any alteration ina structure of a plant's reproductive tissue as compared to a controlplant in which the activity or level of the ARGOS polypeptide has notbeen modulated. “Modulating floral development” further includes anyalteration in the timing of the development of a plant's reproductivetissue (i.e., a delayed or an accelerated timing of floral development)when compared to a control plant in which the activity or level of theARGOS polypeptide has not been modulated. Macroscopic alterations mayinclude changes in size, shape, number, or location of reproductiveorgans, the developmental time period that these structures form, or theability to maintain or proceed through the flowering process in times ofenvironmental stress. Microscopic alterations may include changes to thetypes or shapes of cells that make up the reproductive organs.

The method for modulating floral development in a plant comprisesmodulating ARGOS activity in a plant. In one method, an ARGOS sequenceof the invention is provided. An ARGOS nucleotide sequence can beprovided by introducing into the plant a polynucleotide comprising anARGOS nucleotide sequence of the invention, expressing the ARGOSsequence and thereby modifying floral development. In other embodiments,the ARGOS nucleotide construct introduced into the plant is stablyincorporated into the genome of the plant.

In specific methods, floral development is modulated by decreasing thelevel or activity of the ARGOS polypeptide in the plant. A decrease inARGOS activity can result in at least one or more of the followingalterations in floral development, including, but not limited to,retarded flowering, reduced number of flowers, partial male sterilityand reduced seed set, when compared to a control plant. Inducing delayedflowering or inhibiting flowering can be used to enhance yield in foragecrops such as alfalfa. Methods for measuring such developmentalalterations in floral development are known in the art. See, forexample, Mouradov, et al., (2002) The Plant Cell S111-S130, hereinincorporated by reference.

As discussed above, one of skill will recognize the appropriate promoterto use to modulate floral development of the plant. Exemplary promotersfor this embodiment include constitutive promoters, inducible promoters,shoot-preferred promoters and inflorescence-preferred promoters.

In other methods, floral development is modulated by increasing thelevel and/or activity of the ARGOS sequence of the invention. Suchmethods can comprise introducing an ARGOS nucleotide sequence into theplant and increasing the activity of the ARGOS polypeptide. In othermethods, the ARGOS nucleotide construct introduced into the plant isstably incorporated into the genome of the plant. Increasing expressionof the ARGOS sequence of the invention can modulate floral developmentduring periods of stress. Such methods are described elsewhere herein.Accordingly, the present invention further provides plants havingmodulated floral development when compared to the floral development ofa control plant. Compositions include plants having an increasedlevel/activity of the ARGOS polypeptide of the invention and having analtered floral development. Compositions also include plants having anincreased level/activity of the ARGOS polypeptide of the inventionwherein the plant maintains or proceeds through the flowering process intimes of stress.

Methods are also provided for the use of the ARGOS sequences of theinvention to increase seed size and/or weight. The method comprisesincreasing the activity of the ARGOS sequences in a plant or plant part,such as the seed. An increase in seed size and/or weight comprises anincreased size or weight of the seed and/or an increase in the size orweight of one or more seed part including, for example, the embryo,endosperm, seed coat, aleurone or cotyledon.

As discussed above, one of skill will recognize the appropriate promoterto use to increase seed size and/or seed weight. Exemplary promoters ofthis embodiment include constitutive promoters, inducible promoters,seed-preferred promoters, embryo-preferred promoters andendosperm-preferred promoters.

The method for decreasing seed size and/or seed weight in a plantcomprises decreasing ARGOS activity in the plant. In one embodiment, theARGOS nucleotide sequence can be provided by introducing into the planta polynucleotide comprising a ARGOS nucleotide sequence of theinvention, expressing the ARGOS sequence and thereby decreasing seedweight and/or size. In other embodiments, the ARGOS nucleotide constructintroduced into the plant is stably incorporated into the genome of theplant.

It is further recognized that increasing seed size and/or weight canalso be accompanied by an increase in the speed of growth of seedlingsor an increase in early vigor. As used herein, the term “early vigor”refers to the ability of a plant to grow rapidly during earlydevelopment, and relates to the successful establishment, aftergermination, of a well-developed root system and a well-developedphotosynthetic apparatus. In addition, an increase in seed size and/orweight can also result in an increase in plant yield when compared to acontrol.

Accordingly, the present invention further provides plants having anincreased seed weight and/or seed size when compared to a control plant.In other embodiments, plants having an increased vigor and plant yieldare also provided. In some embodiments, the plant of the invention hasan increased level/activity of the ARGOS polypeptide of the inventionand has an increased seed weight and/or seed size. In other embodiments,such plants have stably incorporated into their genome a nucleic acidmolecule comprising a ARGOS nucleotide sequence of the inventionoperably linked to a promoter that drives expression in the plant cell.

vii. Method of Use for ARGOS Promoter Polynucleotides

The polynucleotides comprising the ARGOS promoters disclosed in thepresent invention, as well as variants and fragments thereof, are usefulin the genetic manipulation of any host cell, preferably plant cell,when assembled with a DNA construct such that the promoter sequence isoperably linked to a nucleotide sequence comprising a polynucleotide ofinterest. In this manner, the ARGOS promoter polynucleotides of theinvention are provided in expression cassettes along with apolynucleotide sequence of interest for expression in the host cell ofinterest. As discussed in Example 2 below, the ARGOS promoter sequencesof the invention are expressed in a variety of tissues and thus thepromoter sequences can find use in regulating the temporal and/or thespatial expression of polynucleotides of interest.

Synthetic hybrid promoter regions are known in the art. Such regionscomprise upstream promoter elements of one polynucleotide operablylinked to the promoter element of another polynucleotide. In anembodiment of the invention, heterologous sequence expression iscontrolled by a synthetic hybrid promoter comprising the ARGOS promotersequences of the invention, or a variant or fragment thereof, operablylinked to upstream promoter element(s) from a heterologous promoter.Upstream promoter elements that are involved in the plant defense systemhave been identified and may be used to generate a synthetic promoter.See, for example, Rushton, et al., (1998) Curr. Opin. Plant Biol.1:311-315. Alternatively, a synthetic ARGOS promoter sequence maycomprise duplications of the upstream promoter elements found within theARGOS promoter sequences.

It is recognized that the promoter sequence of the invention may be usedwith its native ARGOS coding sequences. A DNA construct comprising theARGOS promoter operably linked with its native ARGOS gene may be used totransform any plant of interest to bring about a desired phenotypicchange, such as modulating cell number, modulating root, shoot, leaf,floral and embryo development, stress tolerance and any other phenotypedescribed elsewhere herein.

The promoter nucleotide sequences and methods disclosed herein areuseful in regulating expression of any heterologous nucleotide sequencein a host plant in order to vary the phenotype of a plant. Variouschanges in phenotype are of interest including modifying the fatty acidcomposition in a plant, altering the amino acid content of a plant,altering a plant's pathogen defense mechanism, and the like. Theseresults can be achieved by providing expression of heterologous productsor increased expression of endogenous products in plants. Alternatively,the results can be achieved by providing for a reduction of expressionof one or more endogenous products, particularly enzymes or cofactors inthe plant. These changes result in a change in phenotype of thetransformed plant.

Genes of interest are reflective of the commercial markets and interestsof those involved in the development of the crop. Crops and markets ofinterest change, and as developing nations open up world markets, newcrops and technologies will emerge also. In addition, as ourunderstanding of agronomic traits and characteristics such as yield andheterosis increase, the choice of genes for transformation will changeaccordingly. General categories of genes of interest include, forexample, those genes involved in information, such as zinc fingers,those involved in communication, such as kinases and those involved inhousekeeping, such as heat shock proteins. More specific categories oftransgenes, for example, include genes encoding important traits foragronomics, insect resistance, disease resistance, herbicide resistance,sterility, grain characteristics and commercial products. Genes ofinterest include, generally, those involved in oil, starch, carbohydrateor nutrient metabolism as well as those affecting kernel size, sucroseloading, and the like.

In certain embodiments the nucleic acid sequences of the presentinvention can be used in combination (“stacked”) with otherpolynucleotide sequences of interest in order to create plants with adesired phenotype. The combinations generated can include multiplecopies of any one or more of the polynucleotides of interest. Thepolynucleotides of the present invention may be stacked with any gene orcombination of genes to produce plants with a variety of desired traitcombinations, including but not limited to traits desirable for animalfeed such as high oil genes (e.g., U.S. Pat. No. 6,232,529); balancedamino acids (e.g., hordothionins (U.S. Pat. Nos. 5,990,389; 5,885,801;5,885,802 and 5,703,409); barley high lysine (Williamson, et al., (1987)Eur. J. Biochem. 165:99-106 and WO 1998/20122) and high methionineproteins (Pedersen, et al., (1986) J. Biol. Chem. 261:6279; Kirihara, etal., (1988) Gene 71:359 and Musumura, et al., (1989) Plant Mol. Biol.12:123); increased digestibility (e.g., modified storage proteins (U.S.patent application Ser. No. 10/053,410, filed Nov. 7, 2001) andthioredoxins (U.S. patent application Ser. No. 10/005,429, filed Dec. 3,2001)), the disclosures of which are herein incorporated by reference.The polynucleotides of the present invention can also be stacked withtraits desirable for insect, disease or herbicide resistance (e.g.,Bacillus thuringiensis toxic proteins (U.S. Pat. Nos. 5,366,892;5,747,450; 5,737,514; 5,723,756; 5,593,881; Geiser, et al., (1986) Gene48:109); lectins (Van Damme, et al., (1994) Plant Mol. Biol. 24:825);fumonisin detoxification genes (U.S. Pat. No. 5,792,931); avirulence anddisease resistance genes (Jones, et al., (1994) Science 266:789; Martin,et al., (1993) Science 262:1432; Mindrinos, et al., (1994) Cell78:1089); acetolactate synthase (ALS) mutants that lead to herbicideresistance such as the S4 and/or Hra mutations; inhibitors of glutaminesynthase such as phosphinothricin or basta (e.g., bar gene) andglyphosate resistance (EPSPS gene)) and traits desirable for processingor process products such as high oil (e.g., U.S. Pat. No. 6,232,529);modified oils (e.g., fatty acid desaturase genes (U.S. Pat. No.5,952,544; WO 1994/11516)); modified starches (e.g., ADPGpyrophosphorylases (AGPase), starch synthases (SS), starch branchingenzymes (SBE) and starch debranching enzymes (SDBE)) and polymers orbioplastics (e.g., U.S. Pat. No. 5,602,321; beta-ketothiolase,polyhydroxybutyrate synthase, and acetoacetyl-CoA reductase (Schubert,et al., (1988) J. Bacteriol. 170:5837-5847) facilitate expression ofpolyhydroxyalkanoates (PHAs)), the disclosures of which are hereinincorporated by reference. One could also combine the polynucleotides ofthe present invention with polynucleotides affecting agronomic traitssuch as male sterility (e.g., see, U.S. Pat. No. 5,583,210), stalkstrength, flowering time or transformation technology traits such ascell cycle regulation or gene targeting (e.g., WO 1999/61619; WO2000/17364; WO 1999/25821), the disclosures of which are hereinincorporated by reference.

In one embodiment, sequences of interest improve plant growth and/orcrop yields. For example, sequences of interest include agronomicallyimportant genes that result in improved primary or lateral root systems.Such genes include, but are not limited to, nutrient/water transportersand growth induces. Examples of such genes, include but are not limitedto, maize plasma membrane H⁺-ATPase (MHA2) (Frias, et al., (1996) PlantCell 8:1533-44); AKT1, a component of the potassium uptake apparatus inArabidopsis, (Spalding, et al., (1999) J Gen Physiol 113:909-18); RMLgenes which activate cell division cycle in the root apical cells(Cheng, et al., (1995) Plant Physiol 108:881); maize glutaminesynthetase genes (Sukanya, et al., (1994) Plant Mol Biol 26:1935-46) andhemoglobin (Duff, et al., (1997) J. Biol. Chem 27:16749-16752,Arredondo-Peter, et al., (1997) Plant Physiol. 115:1259-1266;Arredondo-Peter, et al., (1997) Plant Physiol 114:493-500 and referencessited therein). The sequence of interest may also be useful inexpressing antisense nucleotide sequences of genes that that negativelyaffects root development.

Additional, agronomically important traits such as oil, starch andprotein content can be genetically altered in addition to usingtraditional breeding methods. Modifications include increasing contentof oleic acid, saturated and unsaturated oils, increasing levels oflysine and sulfur, providing essential amino acids and also modificationof starch. Hordothionin protein modifications are described in U.S. Pat.Nos. 5,703,049, 5,885,801, 5,885,802 and 5,990,389, herein incorporatedby reference. Another example is lysine and/or sulfur rich seed proteinencoded by the soybean 2S albumin described in U.S. Pat. No. 5,850,016and the chymotrypsin inhibitor from barley, described in Williamson, etal., (1987) Eur. J. Biochem. 165:99-106, the disclosures of which areherein incorporated by reference.

Derivatives of the coding sequences can be made by site-directedmutagenesis to increase the level of preselected amino acids in theencoded polypeptide. For example, the gene encoding the barley highlysine polypeptide (BHL) is derived from barley chymotrypsin inhibitor,U.S. patent application Ser. No. 08/740,682, filed Nov. 1, 1996, and WO1998/20133, the disclosures of which are herein incorporated byreference. Other proteins include methionine-rich plant proteins such asfrom sunflower seed (Lilley, et al., (1989) Proceedings of the WorldCongress on Vegetable Protein Utilization in Human Foods and AnimalFeedstuffs, ed. Applewhite (American Oil Chemists Society, Champaign,Ill.), pp. 497-502, herein incorporated by reference); corn (Pedersen,et al., (1986) J. Biol. Chem. 261:6279; Kirihara, et al., (1988) Gene71:359, both of which are herein incorporated by reference) and rice(Musumura, et al., (1989) Plant Mol. Biol. 12:123, herein incorporatedby reference). Other agronomically important genes encode latex, Floury2, growth factors, seed storage factors and transcription factors.

Insect resistance genes may encode resistance to pests that have greatyield drag such as rootworm, cutworm, European Corn Borer and the like.Such genes include, for example, Bacillus thuringiensis toxic proteingenes (U.S. Pat. Nos. 5,366,892; 5,747,450; 5,736,514; 5,723,756;5,593,881 and Geiser, et al., (1986) Gene 48:109), and the like.

Genes encoding disease resistance traits include detoxification genes,such as against fumonosin (U.S. Pat. No. 5,792,931); avirulence (avr)and disease resistance (R) genes (Jones, et al., (1994) Science 266:789;Martin, et al., (1993) Science 262:1432; and Mindrinos, et al., (1994)Cell 78:1089), and the like.

Herbicide resistance traits may include genes coding for resistance toherbicides that act to inhibit the action of acetolactate synthase(ALS), in particular the sulfonylurea-type herbicides (e.g., theacetolactate synthase (ALS) gene containing mutations leading to suchresistance, in particular the S4 and/or Hra mutations), genes coding forresistance to herbicides that act to inhibit action of glutaminesynthase, such as phosphinothricin or basta (e.g., the bar gene), orother such genes known in the art. The bar gene encodes resistance tothe herbicide basta, the nptII gene encodes resistance to theantibiotics kanamycin and geneticin and the ALS-gene mutants encoderesistance to the herbicide chlorsulfuron.

Sterility genes can also be encoded in an expression cassette andprovide an alternative to physical detasseling. Examples of genes usedin such ways include male tissue-preferred genes and genes with malesterility phenotypes such as QM, described in U.S. Pat. No. 5,583,210.Other genes include kinases and those encoding compounds toxic to eithermale or female gametophytic development.

The quality of grain is reflected in traits such as levels and types ofoils, saturated and unsaturated, quality and quantity of essential aminoacids and levels of cellulose. In corn, modified hordothionin proteinsare described in U.S. Pat. Nos. 5,703,049, 5,885,801, 5,885,802 and5,990,389.

Commercial traits can also be encoded on a gene or genes that couldincrease for example, starch for ethanol production, or provideexpression of proteins. Another important commercial use of transformedplants is the production of polymers and bioplastics such as describedin U.S. Pat. No. 5,602,321. Genes such as β-Ketothiolase, PHBase(polyhydroxyburyrate synthase), and acetoacetyl-CoA reductase (see,Schubert, et al., (1988) J. Bacteriol. 170:5837-5847) facilitateexpression of polyhyroxyalkanoates (PHAs).

Exogenous products include plant enzymes and products as well as thosefrom other sources including procaryotes and other eukaryotes. Suchproducts include enzymes, cofactors, hormones and the like. The level ofproteins, particularly modified proteins having improved amino aciddistribution to improve the nutrient value of the plant, can beincreased. This is achieved by the expression of such proteins havingenhanced amino acid content.

This invention can be better understood by reference to the followingnon-limiting examples. It will be appreciated by those skilled in theart that other embodiments of the invention may be practiced withoutdeparting from the spirit and the scope of the invention as hereindisclosed and claimed.

EXAMPLES Example 1 Isolation of ARGOS Sequences

A routine for identifying all members of a gene family was employed tosearch for the ARGOS genes of interest. A diverse set of all the knownmembers of the gene family as protein sequences was prepared. This dataincludes sequences from other species. These species are searchedagainst a proprietary maize sequence dataset and a nonredundant set ofoverlapping hits is identified. Separately, one takes the nucleotidesequences of any genes of interest in hand and searches against thedatabase and a nonredundant set of all overlapping hits are retrieved.The set of protein hits are then compared to the nucleotide hits. If thegene family is complete, all of the protein hits are contained withinthe nucleotide hits. The ARGOS family of genes consists of 3 Arabidopsisgenes, 8 rice genes, 9 maize genes, 9 sorghum genes and 5 soybean genes.A dendrogram representation of the interrelationship of the proteinsencoded by these genes is provided as FIG. 1.

Example 2 ARGOS Sequence Analysis

The ZmARGOS polypeptides of the current invention have commoncharacteristics with ARGOS genes in a variety of plant species. Therelationship between the genes of the multiple plant species is shown inan alignment, see, FIG. 2. FIG. 3 contains ZmARGOS 1, 2, 3 and AtARGOS 1(SEQ ID NOS: 2, 4, 6 and 26). The proteins encoded by the ARGOS geneshave a well-conserved proline rich region near the C-terminus. TheN-termini are more divergent. The proteins are relatively short,averaging 110 amino acids.

Example 3 Transformation and Regeneration of Transgenic Plants

Immature maize embryos from greenhouse donor plants are bombarded with aplasmid containing the ZmARGOS sequence operably linked to thedrought-inducible promoter RAB17 promoter (Vilardell, et al., (1990)Plant Mol Biol 14:423-432) and the selectable marker gene PAT, whichconfers resistance to the herbicide Bialaphos. Alternatively, theselectable marker gene is provided on a separate plasmid. Transformationis performed as follows. Media recipes follow below.

Preparation of Target Tissue:

The ears are husked and surface sterilized in 30% Clorox® bleach plus0.5% Micro detergent for 20 minutes, and rinsed two times with sterilewater. The immature embryos are excised and placed embryo axis side down(scutellum side up), 25 embryos per plate, on 560Y medium for 4 hoursand then aligned within the 2.5-cm target zone in preparation forbombardment.

Preparation of DNA:

A plasmid vector comprising the ARGOS sequence operably linked to anubiquitin promoter is made. This plasmid DNA plus plasmid DNA containinga PAT selectable marker is precipitated onto 1.1 μm (average diameter)tungsten pellets using a CaCl₂ precipitation procedure as follows:

100 μl prepared tungsten particles in water

10 μl (1 μg) DNA in Tris EDTA buffer (1 μg total DNA)

100 μl 2.5 M CaCl₂

10 μl 0.1 M spermidine

Each reagent is added sequentially to the tungsten particle suspension,while maintained on the multitube vortexer. The final mixture issonicated briefly and allowed to incubate under constant vortexing for10 minutes. After the precipitation period, the tubes are centrifugedbriefly, liquid removed, washed with 500 ml 100% ethanol and centrifugedfor 30 seconds. Again the liquid is removed, and 105 μl 100% ethanol isadded to the final tungsten particle pellet. For particle gunbombardment, the tungsten/DNA particles are briefly sonicated and 10 μlspotted onto the center of each macrocarrier and allowed to dry about 2minutes before bombardment.

Particle Gun Treatment:

The sample plates are bombarded at level #4 in particle gun #HE34-1 or#HE34-2. All samples receive a single shot at 650 PSI, with a total often aliquots taken from each tube of prepared particles/DNA.

Subsequent Treatment:

Following bombardment, the embryos are kept on 560Y medium for 2 days,then transferred to 560R selection medium containing 3 mg/literBialaphos, and subcultured every 2 weeks. After approximately 10 weeksof selection, selection-resistant callus clones are transferred to 288Jmedium to initiate plant regeneration. Following somatic embryomaturation (2-4 weeks), well-developed somatic embryos are transferredto medium for germination and transferred to the lighted culture room.Approximately 7-10 days later, developing plantlets are transferred to272V hormone-free medium in tubes for 7-10 days until plantlets are wellestablished. Plants are then transferred to inserts in flats (equivalentto 2.5″ pot) containing potting soil and grown for 1 week in a growthchamber, subsequently grown an additional 1-2 weeks in the greenhouse,then transferred to classic 600 pots (1.6 gallon) and grown to maturity.Plants are monitored and scored for increased drought tolerance. Assaysto measure improved drought tolerance are routine in the art andinclude, for example, increased kernel-earring capacity yields underdrought conditions when compared to control maize plants under identicalenvironmental conditions. Alternatively, the transformed plants can bemonitored for a modulation in meristem development (i.e., a decrease inspikelet formation on the ear). See, for example, Bruce, et al., (2002)Journal of Experimental Botany 53:1-13.

Bombardment and Culture Media:

Bombardment medium (560Y) comprises 4.0 g/l N6 basal salts (SIGMAC-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000× SIGMA-1511), 0.5 mg/lthiamine HCl, 120.0 g/l sucrose, 1.0 mg/l 2,4-D and 2.88 g/l L-proline(brought to volume with D-I H₂O following adjustment to pH 5.8 withKOH); 2.0 g/l Gelrite® (added after bringing to volume with D-I H₂O) and8.5 mg/l silver nitrate (added after sterilizing the medium and coolingto room temperature). Selection medium (560R) comprises 4.0 g/l N6 basalsalts (SIGMA c-1416), 1.0 ml/L Eriksson's Vitamin Mix (1000×SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/L sucrose and 2.0 mg/l 2,4-D(brought to volume with D-I H₂O following adjustment to pH 5.8 withKOH); 3.0 g/l Gelrite® (added after bringing to volume with D-I H₂O) and0.85 mg/l silver nitrate and 3.0 mg/l bialaphos (both added aftersterilizing the medium and cooling to room temperature).

Plant regeneration medium (288J) comprises 4.3 g/l MS salts (GIBCO11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g nicotinic acid,0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/l glycinebrought to volume with polished D-I H₂O) (Murashige and Skoog, (1962)Physiol. Plant. 15:473), 100 mg/l myo-inositol, 0.5 mg/l zeatin, 60 g/lsucrose, and 1.0 ml/l of 0.1 mM abscisic acid (brought to volume withpolished D-I H₂O after adjusting to pH 5.6); 3.0 g/l Gelrite® (addedafter bringing to volume with D-I H₂O); and 1.0 mg/l indoleacetic acidand 3.0 mg/l bialaphos (added after sterilizing the medium and coolingto 60° C.). Hormone-free medium (272V) comprises 4.3 g/l MS salts (GIBCO11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g/l nicotinicacid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/lglycine brought to volume with polished D-I H₂O), 0.1 g/l myo-inositol,and 40.0 g/l sucrose (brought to volume with polished D-I H₂O afteradjusting pH to 5.6) and 6 g/l Bacto™-agar (added after bringing tovolume with polished D-I H₂O), sterilized and cooled to 60° C.

Example 5 Agrobacterium-Mediated Transformation

For Agrobacterium-mediated transformation of maize with an antisensesequence of the ZmARGOS sequence of the present invention, preferablythe method of Zhao is employed (U.S. Pat. No. 5,981,840 and PCT PatentPublication Number WO 1998/32326, the contents of which are herebyincorporated by reference). Briefly, immature embryos are isolated frommaize and the embryos contacted with a suspension of Agrobacterium,where the bacteria are capable of transferring the ARGOS sequence to atleast one cell of at least one of the immature embryos (step 1: theinfection step). In this step the immature embryos are preferablyimmersed in an Agrobacterium suspension for the initiation ofinoculation. The embryos are co-cultured for a time with theAgrobacterium (step 2: the co-cultivation step). Preferably the immatureembryos are cultured on solid medium following the infection step.Following this co-cultivation period an optional “resting” step iscontemplated. In this resting step, the embryos are incubated in thepresence of at least one antibiotic known to inhibit the growth ofAgrobacterium without the addition of a selective agent for planttransformants (step 3: resting step). Preferably the immature embryosare cultured on solid medium with antibiotic, but without a selectingagent, for elimination of Agrobacterium and for a resting phase for theinfected cells. Next, inoculated embryos are cultured on mediumcontaining a selective agent and growing transformed callus is recovered(step 4: the selection step). Preferably, the immature embryos arecultured on solid medium with a selective agent resulting in theselective growth of transformed cells. The callus is then regeneratedinto plants (step 5: the regeneration step), and preferably calli grownon selective medium are cultured on solid medium to regenerate theplants. Plants are monitored and scored for a modulation in meristemdevelopment. For instance, alterations of size and appearance of theshoot and floral meristems and/or increased yields of leaves, flowersand/or fruits.

Example 6 Over Expression of ZmARGOS Affects Plant Size and Organ Size

The function of the ZmARGOS gene was tested by using transgenic plantsexpressing the Ubi-ZmARGOS transgene. Transgene expression was confirmedby using transgene-specific primer RT-PCR (SEQ ID NO: 38 for ARGOS andSEQ ID NO: 39 for PIN). T1 plants from nine single-copy events wereevaluated in the field. Transgenic plants showed positive growthenhancements in several aspects.

Vegetative Growth and Biomass Accumulation:

Compared to the non transgenic sibs, the transgenic plants (in T1generation) showed an average of 4% increase in plant height across all9 events and up to 12% in the highest event. The stem of the transgenicplants was thicker than the non transgenic siblings as measured by stemdiameter values with an average of 9% to 22% increase among the nineevents. The increase of the plant height and the stem thickness resultedin a larger plant stature and biomass for the transgenic plants.Estimated biomass accumulation showed an increase of 30% on average andup to 57% in transgenic positive lines compared to the negativesiblings.

ZmARGOS was found to impact plant growth mainly through accelerating thegrowth rate but not extending the growth period. The enhanced growth,i.e., increased plant size and biomass accumulation, appears to belargely due to an accelerated growth rate and not due to an extendedperiod of growth because the transgenic plants were not delayed inflowering based on the silking and anthesis dates. In fact, thetransgenic plants flowered earlier than the non-transgenic siblings. Onaverage across the events, the days to flowering was shortened tobetween 30 heat units (1-1.5 days), and 69 heat units (2-2.5 days).Therefore, overexpressing of the ZmARGOS gene accelerated the growthrate of the plant. Accelerated growth rate appears to be associated withan increased cell proliferation rate.

The enhanced vegetative growth, biomass accumulation in transgenics andaccelerated growth rate were further tested with extensive fieldexperiments in both hybrid and inbred backgrounds at advanced generation(T3). Transgenic plants reproducibly showed increased plant height up to18%, stem diameter up to 10%, stalk dry mass up to 15%, increased leafarea up to 14%, total plant dry mass up to 25%. Earlier floweringobserved in T1 generation was again observed in T3 generation.

Reproductive Growth and Grain Yield:

Overexpression of the ZmARGOS1 gene also enhanced the reproductive organgrowth. Ti Transgenic plants showed increased ear length, about 10% onthe average of nine events, and up to 14% for the highest event. Totalkernel weight per ear increased 13% on average and up to 70% for oneevent. The increase in total kernel weight appears to be attributed tothe increased kernel numbers per ear and kernel size. The average of thenine events showed that the kernel number per ear increased 8%, and upto 50% in the highest event. The 100-kernel weight increased 5% onaverage, and up to 13% for the highest event. The positive change inkernel and ear characteristics is associated with grain yield increase.

The enhanced reproductive growth and grain yield of transgenics wasagain confirmed in extensive field experiments at the advancedgeneration (T3). The enhancement was observed in both inbred and hybridbackgrounds. As compared to the non-transgenic sibs as controls, thetransgenic plants showed a significantly increase in primary ear drymass up to 60%, secondary ear dry mass up to 4.7 folds, tassel dry massup to 25% and husk dry mass up to 40%. The transgenics showed up to 13%increase in kernel number per ear, and up to 13% grain yield increase.

Transgenic plants also showed reduced ASI, up to 40 heat units, reducedbarrenness up to 50% and reduced number of aborted kernels up to 64%.The reduction is more when the plants were grown at a high plant densitystressed condition. A reduced measurement of these parameters is oftenrelated to tolerance to biotic stress.

In addition, transgene expression level is significantly correlated withthe ear dry mass.

Example 7 Soybean Embryo Transformation

Soybean embryos are bombarded with a plasmid containing an ARGOSsequence operably linked to an ubiquitin promoter as follows. To inducesomatic embryos, cotyledons, 3-5 mm in length dissected fromsurface-sterilized, immature seeds of the soybean cultivar A2872, arecultured in the light or dark at 26° C. on an appropriate agar mediumfor six to ten weeks. Somatic embryos producing secondary embryos arethen excised and placed into a suitable liquid medium. After repeatedselection for clusters of somatic embryos that multiplied as early,globular-staged embryos, the suspensions are maintained as describedbelow.

Soybean embryogenic suspension cultures can be maintained in 35 mlliquid media on a rotary shaker, 150 rpm, at 26° C. with florescentlights on a 16:8 hour day/night schedule. Cultures are subcultured everytwo weeks by inoculating approximately 35 mg of tissue into 35 ml ofliquid medium.

Soybean embryogenic suspension cultures may then be transformed by themethod of particle gun bombardment (Klein, et al., (1987) Nature(London) 327:70-73, U.S. Pat. No. 4,945,050). A Du Pont BiolisticPDS1000/HE instrument (helium retrofit) can be used for thesetransformations.

A selectable marker gene that can be used to facilitate soybeantransformation is a transgene composed of the 35S promoter fromCauliflower Mosaic Virus (Odell, et al., (1985) Nature 313:810-812), thehygromycin phosphotransferase gene from plasmid pJR225 (from E. coli;Gritz, et al., (1983) Gene 25:179-188) and the 3′ region of the nopalinesynthase gene from the T-DNA of the Ti plasmid of Agrobacteriumtumefaciens. The expression cassette comprising an ARGOS sense sequenceoperably linked to the ubiquitin promoter can be isolated as arestriction fragment. This fragment can then be inserted into a uniquerestriction site of the vector carrying the marker gene.

To 50 μl of a 60 mg/ml 1 μm gold particle suspension is added (inorder): 5 μl DNA (1 μg/μl), 20 μl spermidine (0.1 M), and 50 μl CaCl₂(2.5 M). The particle preparation is then agitated for three minutes,spun in a microfuge for 10 seconds and the supernatant removed. TheDNA-coated particles are then washed once in 400 μl 70% ethanol andresuspended in 40 μl of anhydrous ethanol. The DNA/particle suspensioncan be sonicated three times for one second each. Five microliters ofthe DNA-coated gold particles are then loaded on each macro carrierdisk.

Approximately 300-400 mg of a two-week-old suspension culture is placedin an empty 60×15 mm petri dish and the residual liquid removed from thetissue with a pipette. For each transformation experiment, approximately5-10 plates of tissue are normally bombarded. Membrane rupture pressureis set at 1100 psi, and the chamber is evacuated to a vacuum of 28inches mercury. The tissue is placed approximately 3.5 inches away fromthe retaining screen and bombarded three times. Following bombardment,the tissue can be divided in half and placed back into liquid andcultured as described above.

Five to seven days post bombardment, the liquid media may be exchangedwith fresh media, and eleven to twelve days post-bombardment with freshmedia containing 50 mg/ml hygromycin. This selective media can berefreshed weekly. Seven to eight weeks post-bombardment, green,transformed tissue may be observed growing from untransformed, necroticembryogenic clusters. Isolated green tissue is removed and inoculatedinto individual flasks to generate new, clonally propagated, transformedembryogenic suspension cultures. Each new line may be treated as anindependent transformation event. These suspensions can then besubcultured and maintained as clusters of immature embryos orregenerated into whole plants by maturation and germination ofindividual somatic embryos.

Example 8 Sunflower Meristem Tissue Transformation

Sunflower meristem tissues are transformed with an expression cassettecontaining an ARGOS sequence operably linked to a ubiquitin promoter asfollows (see also, EP Patent

Number EP 0486233, herein incorporated by reference andMalone-Schoneberg, et al., (1994) Plant Science 103:199-207). Maturesunflower seed (Helianthus annuus L.) are dehulled using a singlewheat-head thresher. Seeds are surface sterilized for 30 minutes in a20% Clorox® bleach solution with the addition of two drops of Tween® 20per 50 ml of solution. The seeds are rinsed twice with sterile distilledwater.

Split embryonic axis explants are prepared by a modification ofprocedures described by Schrammeijer, et al., (Schrammeijer, et al.,(1990) Plant Cell Rep. 9:55-60). Seeds are imbibed in distilled waterfor 60 minutes following the surface sterilization procedure. Thecotyledons of each seed are then broken off, producing a clean fractureat the plane of the embryonic axis. Following excision of the root tip,the explants are bisected longitudinally between the primordial leaves.The two halves are placed, cut surface up, on GBA medium consisting ofMurashige and Skoog mineral elements (Murashige, et al., (1962) Physiol.Plant., 15:473-497), Shepard's vitamin additions (Shepard, (1980) inEmergent Techniques for the Genetic Improvement of Crops (University ofMinnesota Press, St. Paul, Minn.), 40 mg/l adenine sulfate, 30 g/lsucrose, 0.5 mg/l 6-benzyl-aminopurine (BAP), 0.25 mg/l indole-3-aceticacid (IAA), 0.1 mg/l gibberellic acid (GA₃), pH 5.6, and 8 g/l Phytagar.

The explants are subjected to microprojectile bombardment prior toAgrobacterium treatment (Bidney, et al., (1992) Plant Mol. Biol.18:301-313). Thirty to forty explants are placed in a circle at thecenter of a 60×20 mm plate for this treatment. Approximately 4.7 mg of1.8 mm tungsten microprojectiles are resuspended in 25 ml of sterile TEbuffer (10 mM Tris HCl, 1 mM EDTA, pH 8.0) and 1.5 ml aliquots are usedper bombardment. Each plate is bombarded twice through a 150 mm nytexscreen placed 2 cm above the samples in a PDS 1000® particleacceleration device.

Disarmed Agrobacterium tumefaciens strain EHA105 is used in alltransformation experiments. A binary plasmid vector comprising theexpression cassette that contains the ARGOS gene operably linked to theubiquitin promoter is introduced into Agrobacterium strain EHA105 viafreeze-thawing as described by Holsters, et al., (1978) Mol. Gen. Genet.163:181-187. This plasmid further comprises a kanamycin selectablemarker gene (i.e, nptII). Bacteria for plant transformation experimentsare grown overnight (28° C. and 100 RPM continuous agitation) in liquidYEP medium (10 gm/l yeast extract, 10 gm/l Bacto®peptone, and 5 gm/lNaCl, pH 7.0) with the appropriate antibiotics required for bacterialstrain and binary plasmid maintenance. The suspension is used when itreaches an OD₆₀₀ of about 0.4 to 0.8. The Agrobacterium cells arepelleted and resuspended at a final OD₆₀₀ of 0.5 in an inoculationmedium comprised of 12.5 mM MES pH 5.7, 1 gm/l NH₄Cl, and 0.3 gm/lMgSO₄.

Freshly bombarded explants are placed in an Agrobacterium suspension,mixed, and left undisturbed for 30 minutes. The explants are thentransferred to GBA medium and co-cultivated, cut surface down, at 26° C.and 18-hour days. After three days of co-cultivation, the explants aretransferred to 374B (GBA medium lacking growth regulators and a reducedsucrose level of 1%) supplemented with 250 mg/l cefotaxime and 50 mg/lkanamycin sulfate. The explants are cultured for two to five weeks onselection and then transferred to fresh 374B medium lacking kanamycinfor one to two weeks of continued development. Explants withdifferentiating, antibiotic-resistant areas of growth that have notproduced shoots suitable for excision are transferred to GBA mediumcontaining 250 mg/l cefotaxime for a second 3-day phytohormonetreatment. Leaf samples from green, kanamycin-resistant shoots areassayed for the presence of NPTII by ELISA and for the presence oftransgene expression by assaying for a modulation in meristemdevelopment (i.e., an alteration of size and appearance of shoot andfloral meristems).

NPTII-positive shoots are grafted to Pioneer® hybrid 6440 in vitro-grownsunflower seedling rootstock. Surface sterilized seeds are germinated in48-0 medium (half-strength Murashige and Skoog salts, 0.5% sucrose, 0.3%Gelrite®, pH 5.6) and grown under conditions described for explantculture. The upper portion of the seedling is removed, a 1 cm verticalslice is made in the hypocotyl, and the transformed shoot inserted intothe cut. The entire area is wrapped with Parafilm® to secure the shoot.Grafted plants can be transferred to soil following one week of in vitroculture. Grafts in soil are maintained under high humidity conditionsfollowed by a slow acclimatization to the greenhouse environment.Transformed sectors of T₀ plants (parental generation) maturing in thegreenhouse are identified by NPTII ELISA and/or by ARGOS activityanalysis of leaf extracts while transgenic seeds harvested fromNPTII-positive T₀ plants are identified by ARGOS activity analysis ofsmall portions of dry seed cotyledon.

An alternative sunflower transformation protocol allows the recovery oftransgenic progeny without the use of chemical selection pressure. Seedsare dehulled and surface-sterilized for 20 minutes in a 20% Clorox®bleach solution with the addition of two to three drops of Tween® 20 per100 ml of solution, then rinsed three times with distilled water.Sterilized seeds are imbibed in the dark at 26° C. for 20 hours onfilter paper moistened with water. The cotyledons and root radical areremoved, and the meristem explants are cultured on 374E (GBA mediumconsisting of MS salts, Shepard vitamins, 40 mg/l adenine sulfate, 3%sucrose, 0.5 mg/l 6-BAP, 0.25 mg/l IAA, 0.1 mg/l GA, and 0.8% Phytagarat pH 5.6) for 24 hours under the dark. The primary leaves are removedto expose the apical meristem, around 40 explants are placed with theapical dome facing upward in a 2 cm circle in the center of 374M (GBAmedium with 1.2% Phytagar), and then cultured on the medium for 24 hoursin the dark.

Approximately 18.8 mg of 1.8 μm tungsten particles are resuspended in150 μl absolute ethanol. After sonication, 8 μl of it is dropped on thecenter of the surface of macrocarrier. Each plate is bombarded twicewith 650 psi rupture discs in the first shelf at 26 mm of Hg helium gunvacuum.

The plasmid of interest is introduced into Agrobacterium tumefaciensstrain EHA105 via freeze thawing as described previously. The pellet ofovernight-grown bacteria at 28° C. in a liquid YEP medium (10 g/l yeastextract, 10 g/l Bacto®peptone and 5 g/l NaCl, pH 7.0) in the presence of50 μg/l kanamycin is resuspended in an inoculation medium (12.5 mM 2-mM2-(N-morpholino) ethanesulfonic acid, MES, 1 g/l NH₄Cl and 0.3 g/l MgSO₄at pH 5.7) to reach a final concentration of 4.0 at OD₆₀₀.Particle-bombarded explants are transferred to GBA medium (374E), and adroplet of bacteria suspension is placed directly onto the top of themeristem. The explants are co-cultivated on the medium for 4 days, afterwhich the explants are transferred to 374C medium (GBA with 1% sucroseand no BAP, IAA, GA3 and supplemented with 250 μg/ml cefotaxime). Theplantlets are cultured on the medium for about two weeks under 16-hourday and 26° C. incubation conditions.

Explants (around 2 cm long) from two weeks of culture in 374C medium arescreened for a modulation in meristem development (i.e., an alterationof size and appearance of shoot and floral meristems). After positive(i.e., a change in ARGOS expression) explants are identified, thoseshoots that fail to exhibit an alteration in ARGOS activity arediscarded, and every positive explant is subdivided into nodal explants.One nodal explant contains at least one potential node. The nodalsegments are cultured on GBA medium for three to four days to promotethe formation of auxiliary buds from each node. Then they aretransferred to 374C medium and allowed to develop for an additional fourweeks. Developing buds are separated and cultured for an additional fourweeks on 374C medium. Pooled leaf samples from each newly recoveredshoot are screened again by the appropriate protein activity assay. Atthis time, the positive shoots recovered from a single node willgenerally have been enriched in the transgenic sector detected in theinitial assay prior to nodal culture.

Recovered shoots positive for altered ARGOS expression are grafted toPioneer® hybrid 6440 in vitro-grown sunflower seedling rootstock. Therootstocks are prepared in the following manner. Seeds are dehulled andsurface-sterilized for 20 minutes in a 20% Clorox® bleach solution withthe addition of two to three drops of Tween® 20 per 100 ml of solution,and are rinsed three times with distilled water. The sterilized seedsare germinated on the filter moistened with water for three days, thenthey are transferred into 48 medium (half-strength MS salt, 0.5%sucrose, 0.3% Gelrite® pH 5.0) and grown at 26° C. under the dark forthree days, then incubated at 16-hour-day culture conditions. The upperportion of selected seedling is removed, a vertical slice is made ineach hypocotyl, and a transformed shoot is inserted into a V-cut. Thecut area is wrapped with Parafilm®. After one week of culture on themedium, grafted plants are transferred to soil. In the first two weeks,they are maintained under high humidity conditions to acclimatize to agreenhouse environment.

Example 9 Variants of ARGOS Sequences

A. Variant Nucleotide Sequences of ARGOS that do not Alter the EncodedAmino Acid Sequence

The ARGOS nucleotide sequences are used to generate variant nucleotidesequences having the nucleotide sequence of the open reading frame withabout 70%, 75%, 80%, 85%, 90% and 95% nucleotide sequence identity whencompared to the starting unaltered ORF nucleotide sequence of thecorresponding SEQ ID NO. These functional variants are generated using astandard codon table. While the nucleotide sequence of the variants arealtered, the amino acid sequence encoded by the open reading frames donot change.

B. Variant Amino Acid Sequences of ARGOS Polypeptides

Variant amino acid sequences of the ARGOS polypeptides are generated. Inthis example, one amino acid is altered. Specifically, the open readingframes are reviewed to determine the appropriate amino acid alteration.The selection of the amino acid to change is made by consulting theprotein alignment (with the other orthologs and other gene familymembers from various species). An amino acid is selected that is deemednot to be under high selection pressure (not highly conserved) and whichis rather easily substituted by an amino acid with similar chemicalcharacteristics (i.e., similar functional side-chain). Using the proteinalignment set forth in FIG. 2, an appropriate amino acid can be changed.Once the targeted amino acid is identified, the procedure outlined inthe following section C is followed. Variants having about 70%, 75%,80%, 85%, 90% and 95% nucleic acid sequence identity are generated usingthis method.

C. Additional Variant Amino Acid Sequences of ARGOS Polypeptides

In this example, artificial protein sequences are created having 80%,85%, 90% and 95% identity relative to the reference protein sequence.This latter effort requires identifying conserved and variable regionsfrom the alignment set forth in FIG. 2 and then the judiciousapplication of an amino acid substitutions table. These parts will bediscussed in more detail below.

Largely, the determination of which amino acid sequences are altered ismade based on the conserved regions among ARGOS protein or among theother ARGOS polypeptides. Based on the sequence alignment, the variousregions of the ARGOS polypeptide that can likely be altered arerepresented in lower case letters, while the conserved regions arerepresented by capital letters. It is recognized that conservativesubstitutions can be made in the conserved regions below withoutaltering function. In addition, one of skill will understand thatfunctional variants of the ARGOS sequence of the invention can haveminor non-conserved amino acid alterations in the conserved domain.

Artificial protein sequences are then created that are different fromthe original in the intervals of 80-85%, 85-90%, 90-95% and 95-100%identity. Midpoints of these intervals are targeted, with liberallatitude of plus or minus 1%, for example. The amino acids substitutionswill be effected by a custom Perl script. The substitution table isprovided below in Table 3.

TABLE 3 Substitution Table Strongly Similar and Rank of Optimal Order toAmino Acid Substitution Change Comment I L, V 1 50:50 substitution L I,V 2 50:50 substitution V I, L 3 50:50 substitution A G 4 G A 5 D E 6 E D7 W Y 8 Y W 9 S T 10 T S 11 K R 12 R K 13 N Q 14 Q N 15 F Y 16 M L 17First methionine cannot change H Na No good substitutes C Na No goodsubstitutes P Na No good substitutes

First, any conserved amino acids in the protein that should not bechanged is identified and “marked off” for insulation from thesubstitution. The start methionine will of course be added to this listautomatically. Next, the changes are made.

H, C and P are not changed in any circumstance. The changes will occurwith isoleucine first, sweeping N-terminal to C-terminal. Then leucine,and so on down the list until the desired target it reached. Interimnumber substitutions can be made so as not to cause reversal of changes.The list is ordered 1-17, so start with as many isoleucine changes asneeded before leucine, and so on down to methionine. Clearly many aminoacids will in this manner not need to be changed. L, I and V willinvolve a 50:50 substitution of the two alternate optimal substitutions.

The variant amino acid sequences are written as output. Perl script isused to calculate the percent identities. Using this procedure, variantsof the ARGOS polypeptides are generating having about 80%, 85%, 90% and95% amino acid identity to the starting unaltered ORF nucleotidesequence of SEQ ID NOS: 1, 3, 5 and 40-71.

All publications and patent applications in this specification areindicative of the level of ordinary skill in the art to which thisinvention pertains. All publications and patent applications are hereinincorporated by reference to the same extent as if each individualpublication or patent application was specifically and individuallyindicated by reference.

The invention has been described with reference to various specific andpreferred embodiments and techniques. However, it should be understoodthat many variations and modifications may be made while remainingwithin the spirit and scope of the invention.

What is claimed is:
 1. An isolated polynucleotide selected from thegroup consisting of: a. a polynucleotide having at least 70% sequenceidentity, as determined by the GAP algorithm under default parameters,to the full length sequence of a polynucleotide selected from the groupconsisting of SEQ ID NOS: 1, 3, 5 and 40-71; wherein the polynucleotideencodes a polypeptide that functions as a modifier of organ size; b. apolynucleotide encoding a polypeptide selected from the group consistingof SEQ ID NOS: 2, 4 and 6-37; and c. a polynucleotide selected from thegroup consisting of SEQ ID NOS: 1, 3, 5 and 40-71; and d. Apolynucleotide which is complementary to the polynucleotide of (a), (b)or (c).
 2. A recombinant expression cassette, comprising thepolynucleotide of claim 1, wherein the polynucleotide is operablylinked, in sense or anti-sense orientation, to a promoter.
 3. A hostcell comprising the expression cassette of claim
 2. 4. A transgenicplant comprising the recombinant expression cassette of claim
 2. 5. Thetransgenic plant of claim 4, wherein said plant is a monocot.
 6. Thetransgenic plant of claim 4, wherein said plant is a dicot.
 7. Thetransgenic plant of claim 4, wherein said plant is selected from thegroup consisting of: maize, soybean, sunflower, sorghum, canola, wheat,alfalfa, cotton, rice, barley, millet, peanut and cocoa.
 8. A transgenicseed from the transgenic plant of claim
 4. 9. A method of modulatingorgan size in plants, comprising: a. introducing into a plant cell arecombinant expression cassette comprising the polynucleotide of claim 1operably linked to a promoter; and b. culturing the plant under plantcell growing conditions; wherein the organ size in said plant cell ismodulated.
 10. The method of claim 9, wherein the plant cell is from aplant selected from the group consisting of: maize, soybean, sunflower,sorghum, canola, wheat, alfalfa, cotton, rice, barley, millet, peanutand cocoa.
 11. A method of modulating the whole plant or organ size in aplant, comprising: a. introducing into a plant cell a recombinantexpression cassette comprising the polynucleotide of claim 1 operablylinked to a promoter; b. culturing the plant cell under plant cellgrowing conditions; and c. regenerating a plant form said plant cell;wherein the organ size in said plant is modulated.
 12. The method ofclaim 11, wherein the plant is selected from the group consisting of:maize, soybean, sorghum, canola, wheat, alfalfa, cotton, rice, barley,millet, peanut and cocoa.
 13. A product derived from the method ofprocessing of transgenic plant tissues expressing an isolatedpolynucleotide encoding an ARGOS gene, the method comprising: a.transforming a plant cell with a recombinant expression cassettecomprising a polynucleotide having at least 90% sequence identity to thefull length sequence of a polynucleotide selected from the groupconsisting of SEQ ID NO: 1, 3, 5 and 40-71, operably linked to apromoter; and b. culturing the transformed plant cell under plant cellgrowing conditions; wherein the growth in said transformed plant cell ismodulated; c. growing the plant cell under plant-forming conditions toexpress the polynucleotide in the plant tissue; and d. processing theplant tissue to obtain a product.
 14. A product according to claim 13,wherein the polynucleotide further encodes a polypeptide selected fromthe group consisting of SEQ ID NO: 2, 4 and 6-37.
 15. The transgenicplant of claim 13, wherein the plant is a monocot.
 16. The transgenicplant of claim 13, wherein the plant is selected from the groupconsisting of: maize, soybean, sunflower, sorghum, canola, wheat,alfalfa, cotton, rice, barley and millet.
 17. A product according toclaim 13, which improves stalk strength of a plant by overexpression ofthe polynucleotide.
 18. A product according to claim 13, which increasesyield by increasing biomass.
 19. A product according to claim 13, whichis a constituent of ethanol.